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ABSTRACT 
CHEMICAL, BIOLOGICAL AND PRELIMINARY IN VITRO STUDIES OF NOVEL 
VANADIUM(IV) COMPLEXES WITH SCHIFF BASES AND 
THIOSEMICARBAZONE LIGANDS  
by Nerissa Lewis 
December 2011 
9-Anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC), potassium (E)-2-(2-
hydroxybenzylideneamino)-3-(1H-indol-3-yl)propanoate (K[(Sal-L-tryp)] 
and 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid (the reduced Schiff 
base) were prepared using known synthetic procedures. Two novel thiosemicarbazone 
ligands, (E)-N-ethyl-2-(4-hydroxy-3-methoxybenzylidene)hydrazinecarbothioamide (N-
Ethhymethohcarbthio) and (E)-N-ethyl-2-(1-(thiazol-2-
yl)ethylidene)hydrazinecarbothioamide (acetylethTSC), were also prepared. All ligands 
were characterized by FT IR and electrochemistry. N-Ethhymethohcarbthio were 
characterized by elemental analysis whereas the reduced Schiff base and K[(Sal-L-tryp)] 
were characterized by ESI MS. X-ray crystallography was also used to characterize 
acetylethTSC. The ligands were then reacted with [VO(Sal-L-tryp)(H2O)] (1) (Sal-L-tryp 
= N-salicylidene-L-tryptophanate) to produce the novel complexes, [VO(Sal-L-
tryp)(MeATSC)].1.5C2H5OH (2), [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O (3), 
and [VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH (4), respectively.   All complexes were 
characterized by elemental analysis, ESI MS, IR, UV-visible, 
1
H and
 13
C NMR 
spectroscopy, and electrochemistry.  Oxidized DMSO and DMSO-d6 solutions of each  
 
 iii 
 
complex were also characterized by ESI MS and 
1
H NMR spectroscopy.  [VO(Sal-L-
tryp)(MeATSC)].1.5C2H5OH, [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O, and 
[VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH were observed to exhibit anti-proliferative 
activity against three colon cancer cell lines, HTC-116, Caco-2, and HT-29.  When the 
anti-proliferative effects were compared with that of non-cancerous colonic 
myofibroblasts, less inhibition was observed. The results obtained suggest that these 
compounds can be used as potential chemotherapeutic agents. 
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CHAPTER I 
INTRODUCTION 
Vanadium History 
Vanadium was first discovered by the Spanish-Mexican mineralogist Andrés del 
Río in the year 1813.
1,2
 The element was given the name vanadium, after Vanadis, the 
Norse goddess of love and beauty (Figure 1), due to the variety of colors formed in 
solution upon changes in concentration and pH.
1-3
 Vanadium is therefore the only 
element in the periodic table that is named after a goddess.
4
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1. A painting of “Vanadis” the Norse goddess of love and beauty.5  
2 
 
 
Vanadium is a widely dispersed element found at generally low concentrations in 
approximately 65 minerals including patronite (VS4), vanadinite (Pb5(VO4)3Cl) and 
carnotite (K2(UO2)2(VO4)2.3H2O).
6
 As a trace element, vanadium is known to occur at 
extremely low concentrations in mammalian tissues and is essential for many mammalian 
species distributed on earth.
3,7,8
 Although the exact function of this element remains 
unclear, vanadium is known to be beneficial and possibly essential for humans and some 
living organisms.
3,9-13
   
Vanadium Chemistry 
Vanadium is the 23
rd
 element of the periodic table and is known to possess 
numerous chemical and biochemical properties.
3,4,7
 Vanadium, a typical first row 
transition metal, is a silvery grey metal which has an electronic configuration of [Ar] 
3d
3
4s
2
.
14,15
 Vanadium displays a wide variety of oxidation states and varying geometries 
(Table 1).
4,7,16
 The most common oxidation states of vanadium are V
2+
, V
3+
, V
4+
 and V
5+
 
for which the corresponding electronic configurations are [Ar] 3d
3
, [Ar] 3d
2
, [Ar] 3d
1
 and 
[Ar] 3d
0
, respectively.
14
 Given the varying possible oxidation states of vanadium, the 
partial pressure of oxygen p[O2] is a very strong factor for reactions involving 
vanadium.
14
 In aqueous solutions, (V(III)) is the lowest oxidation state of vanadium that 
is relatively stable.
3
  
The aqueous chemistry of V(II) are very sparse in literature. The most commonly 
mentioned aqua V(II) species is the [V(H2O)6]
2+
 as shown in Table 1. The aqueous 
chemistry of V(III) has been studied to a much lesser extent than that of V(IV) and 
V(V).
3,17-20
 V(III) complexes are known to form numerous mononuclear, binuclear, and 
 
3 
 
 
Table 1 
Variety of oxidation states and geometries exhibited by vanadium.
16
 
 
Oxidation 
State 
 
Coordination 
number 
 
Geometry 
 
Examples 
V
-1
, d
6 
V
0
, d
5 
V
1
, d
4 
 
 
 
6 
6 
6 
 
7 
 
 
Octahedral 
Octahedral 
Octahedral 
Tetragonal pyramidal 
Monocapped octahedral 
 
 
V(CO)
-
6, Li[V(bipy)3].4C4H8O 
V(CO)
-
6, V(bipy)3, V[C2H4(PMe2)2]3 
[V(bipy)3]
+ 
5
-C5H5V(CO)4 
[V[(CO)3(PMe3)4]
+
, V(CO)2(dmpe)2Cl 
 
V
II
, d
3 
4 
 
5 
6
a
 
 
Almost planar 
 
Sp 
Octahedral 
 
[Li(THF)]2V(2,6-
diisopropylphenolate)4] 
(2,6-Ph2C6H3O)2V(py)3 
[V(H2O)6]
2+
, [V(CN)6]
4- 
 
V
III
, d
2
 
3 
4 
5 
6
a
 
7 
 
Planar 
Tetrahedral 
tbq 
Octahedral 
Pentagonal bipyramidal 
 
V[N(SiMe3)2]3, V[CH(SiMe3)3]3 
[VCl4]
-
 
trans-VCl3(SMe2)2, VCl3(NMe3)2 
[V(NH3)6]
3+
, [V(C2O4)]
3-
, VF 
K4[V(CN)7].2H2O 
 
 
 
V
IV
, d
1 
 
 
 
 
 
 
 
 
 
 
 
V
V
, d
0 
 
 
 
 
 
4 
5 
 
 
6 
 
8 
 
4 
5 
 
 
6a 
 
7 
 
 
Tetrahedral 
Tetragonal pyramidal 
sp 
tbp 
Octahedral 
 
Dodecahedral 
 
Tetrahedral  
tbp 
sp 
 
Octahedral 
 
Pentagonal bipyramidal 
 
 
VCl4, V(NEt2)4, V(CH2SiMe3)4 
VO(acac)2, PCl4
+
VCl5
-
 
[V2O4(OH)2(PhPO3)4]
2+
 
VOCl2 trans-(NMe3)2 
VO2(rutile), K2VCl6, VO(acac)2(py), 
VO(acac)2Cl2 
VCl4(diars)2, V(S2CMe)4 
 
VOCl3 
VF5(g), VNCl2(quinuclidine)2 
CsVOF4 
 
VF5(s), VF6
-
, V2O5, [VO2(ox)2]
3-
,V2S5 
 
VO(NO3)3.CH3CN, VO(Et2NCS2)3 
 
 
 
4 
 
 
species of high nuclearities which introduces ambiguity when attempting to identify the 
actual species that is present in solution.
21
  
Due to the presence of unpaired electrons, vanadium compounds of lower 
oxidation states are paramagnetic in nature and generally exist as colored compounds.
22
 
V(III) complexes are therefore NMR silent, leading to further complications in the 
analysis of the species present in solution.
21
 V(III) solutions are also easily oxidized (E
0
 = 
+0.34 V (vs NHE)) (Equation 1)
23
 and therefore requires stringent anaerobic conditions 
during speciation studies.
3  
 
VO
2+
 + 2H
+
 + 2e
-
  V
3+
 + H2O                  ………………..  (1) 
 
V(III) compounds therefore require strongly acidic conditions or the presence of a potent 
chelator in order to exist in aqueous solutions.
3
 These compounds generally form 
octahedral complexes, such as [V(H2O)6]
3+
, [VCl2(MeOH)4]
+
, [V(NCS)6]
3-
, and 
[VCl2(THF)2(H2O)2]
+
.
3,24
 
The aqua V(III) ion, [V(H2O)6]
3+
,
 
is greenish blue in color and is mainly obtained 
from electrolytic or chemical reduction of V(IV) and V(V).
3
 Under strongly acidic 
conditions, V(III) ions predominate as [V(H2O)6]
3+ 
ions (at pH < 1) and as 
[V(OH)(H2O)5]
2+  
ions (at pH = 1.0 - 3.5) (Figure 2).
3
 As the pH increases further (1.0 < 
pH < 3.5), V(III) ions undergo dimerization to form [V2( 2-O)(H2O)10]
4+ 
(Figure 2).
3,18 
Upon further increase in pH, the trinuclear [V3(OH)8(H2O)10]
+  
and tetranuclear  
 
5 
 
 
 
Figure 2.  Polymeric V(III) species.
3
  
[V4(OH)12(H2O)12] species are formed at pH > 3.5 (Figure 2).
3,18
 As the pH exceeds a 
value of 4.5 (pH > 4.5), an insoluble solid usually referred to as (V(OH)3)n then begins to 
form in solution which emphasizes the need for a strong chelation to remove soluble 
V(III) that may still be present at neutral pH.
3,25,26
  
V(IV) complexes are paramagnetic in nature and generally forms compounds that 
are colorless, pale yellow or red in color.
22
 V(IV) compounds exists primarily in a square 
pyramidal or peuedo-octahedral coordination, as the hydrated vanadyl cation, 
[VO(H2O)5]
2+
 (VO
2+
) (Figure 3).
3,27
 The vanadyl cation, formed by dissolving VOSO4 
 
 
Figure 3.  Structure of the most common vanadyl cation.
3
 
6 
 
 
in acidic aqueous solutions, is probably the most stable diatomic ion and is known to be 
present in approximately 98% of all V(IV) solid compounds and aqueous solutions.
24,27-29
  
The VO
2+ 
cation is known to form many complexes and the identity of this ion is 
retained throughout a wide variety of reactions.
24
 This cation is very stable under acidic 
conditions and is the main species present in solution at pH 3.
3,30
 As the pH is increased 
into the physiological range, several oligomeric and polymeric spin-paired species are 
then formed.
27
  The speciation of V(IV) species at nanomolar to submicromolar and at 
millimolar concentrations of V(IV) is shown in Schemes 1 and 2, respectively.
3
 As 
shown in Schemes 1 and 2, as pH increases (pH ~ 4), a proton is loss resulting in the 
formation of the hydrolyzed species, [VO(H2O)4(OH)]
+
 species.
3
   
 
 
Scheme 1.
 
Aqueous [VO(OH2)5]
2+
 Hydrolysis Products at Nano to Submicromolar 
Concentrations of V(IV).
3
 The insoluble hydroxide VO(OH)2 n is in equilibrium with 
the positively and negatively charged monomeric species.  
  
 
 
Scheme 2.  Aqueous [VO(OH2)5]
2+
 Hydrolysis Products at Micro to Millimolar 
Concentrations of V(IV).
3
  
 
7 
 
 
As the pH increases further (pH>5), an insoluble VO(OH)2 n species is formed, 
which dissolves to form a binuclear species ([(VO)2(OH)5]
-
), and a subsequent 
monomeric species [VO(OH)3]
-
 upon further increase in pH.
3,31
 In the speciation diagram 
(Figure 4), the existence of negatively charged monomeric V(IV) species at neutral pH is 
clearly illustrated.
3
 Figure 4 displays a diagram of the V(IV) species that generally exist 
in aqueous solutions.
3
 Extensive studies have been carried out on the aqueous chemistry 
of V(V) ions, which are readily solvated in aqueous solutions to form the hydrated 
[V(OH2)n]
5+
 species.
32
 According to thermodynamic evidence, when compared with 
 
Figure 4.  Predominance area diagram for aqueous V(IV) species, which is represented as 
the logarithm of the total molar concentration of vanadium(IV) against  pH. Solid lines 
represent the condition where the concentrations of two soluble species in equilibrium.
3
 
“Reprinted with permission from Crans, D. C.; Smee, J. J.; Gaidamauskas, E.; Yang, L. 
Chem. Rev. 2004, 104, 849. Copyright 2004 by the American Chemical Society.”  
 
8 
 
 
H3VO4, the high stability of the vanadate ion (VO4
+
) is often accounted for by an increase 
in coordination number.
3,33
 The pH of the solution and the concentration of the vanadium 
oxide are two critical factors for determining the identity of the specific vanadium oxide 
present in aqueous solution.
7,15
 V(V) readily hydrolyzes to form twelve different species 
consisting of both monomeric and polymeric species.
15,34
 The strong polarizing power of 
the V(V) ion leads to an increase in the acidity solutions due to the partial dissociation of 
coordinated water molecules (Equation 2).
32
 
 
[V
V
(OH2)6]
5+
 + nH2O   [V
V
(OH)n(OH2)6-n]
(5-n)+
 + nH3O
+ 
   .………...    (2) 
                                                                                              
 
 
The existence of various oxides of vanadium at varying pH is illustrated in the 
Pourbaix diagram shown in Figure 5.
30
 The Pourbaix diagram clearly indicates the 
existence of V(V) species at higher pH and the subsequent existence of V(IV) species at 
low pH.
3,35,36
 In Figures 5a and 5b, it is also observed that vanadium exists mainly as 
cationic species at pH < 3, and as anionic species pH > 3.5.30  In aqueous solutions, the 
decameric species, [V10O28]6-, and its protonated forms are the major V(V) species 
present.
3,37
 Due to the instability of this compound, [V10O28]6- often serves as a 
thermodynamic sink in solutions at pH = 3-6.
3,37 
V(V) compounds generally forms a variety of polyoxoanions and may exist in a 
tetrahedral (VO4), pentahedral (VO5) or octahedral (VO6) coordination environments.
3
 At 
physiological pH, the vanadate mononuclear species exists predominantly in the 
monomeric form as the H2VO4
-
 ion.
3,27,38,39
 In the presence of nucleophillic ligands, 
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Figure 5.   Potential–pH diagrams for the vanadium–water system at 298.15 K: (a) 
activities of dissolved vanadium of 10
-2
 and (b) activities of dissolved vanadium of 10
-6
.
30
 
Reproduced with permission from Hydrometallurgy 2011, 106,105. Copyright 2011 by 
Elsevier. 
  
monomeric vanadate readily undergoes various condensation reactions to form numerous 
species in solution (Figure 6).
3
  
10 
 
 
 
 
Figure 6.  Structures of the major deprotonated oxovanadium(V) ions.
3,41,42
 
 
Vanadium pentoxide (V2O5) is amphoteric in nature and readily dissolves in 
strong aqueous alkali to form colorless solutions, consisting mainly of VO4
3-
.
40
 As the 
acidity of the solution is increased, the colorless solution deepens in color, and changes 
from orange to red (just below neutral pH).
40
 As the acidity is further increased, a 
brown precipitate of V2O5 is formed, which readily dissolves at lower pH to give a pale-
yellow solution.
40
 The existence of various vanadate species in aqueous solutions is 
dependent on the pH and total concentration of vanadium in solution.
40
 The predominant 
oligomer formed under acidic conditions (2 ≤ pH ≤ 6) is the yellow-orange 
decavanadate ion [V10O28]
6-
 (V10)  which is capable of existing in several protonated 
forms (Scheme 3).
16
 Upon further addition of acid, the [V10O28]
6-
 readily forms the 
dioxovanadium(V) ion (VO2
+
).
16
 The main oligomeric species present from pH 6 to 10 
includes the dimeric [V2O7]
4-
 ion (V2), the cyclic tetrameric [V4O12]
4-
 ion (V4), and the 
cyclic pentameric [V5O15]
4-
 ion (V5), which are all colorless.
27,43,44
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Scheme 3.  Protonated forms of decavanadate ion.
16
 
 
Schiff Base Complexes of Vanadium 
 Schiff bases are considered to be a very important class of compounds that are 
widely used due to their good solubility properties and their remarkable versatility.
45
 
Schiff bases and their metal complexes are known to exhibit a broad variety of biological 
activity such as anti-viral,
46
 anti-parasitic,
47
 anti-bacterial,
48
 anti-inflammatory,
49
 anti-
tumor,
50,51
 anti-HIV,
52
 anti-cancer,
53
 etc. 
    According to Sen et al.,
54
 metal complexes containing salen-type Schiff bases 
are capable of exhibiting unusual coordination, high thermodynamic stability and kinetic 
inertness.
54
 Schiff bases display interesting asymmetric catalytic activity, and their metal 
complexes are of great interest as enzyme models since they are capable of mimicking 
biological sites.
54
 
Recently, the use of heterogenized V
IV
O and V
V
O2 complexes as catalysts for the 
functionalization of alkenes were reported by Maurya et al.
55
 Previously, the 
encapsulation of [V
V
O2(Sal-aebmz)] (Hsal-aebmz = Schiff base derived from 
salicylaldehyde and 2-aminoethylbenzimidazole) in zeolite-Y (where the zeolite acts as a 
protein mantle) was shown to significantly improve the catalytic activity of the zeolite by 
yielding a higher turnover frequency. This catalyst (or catalyst precursor) was also found 
12 
 
 
to be easily recyclable and maintain their activity for several cycles of catalytic use.
55
 In 
their present study, the catalytic activity of similar V
IV
O and V
V
O2 complexes containing 
ligands 10 (Hpydx-aebmz) and 11 (Hpydx-ambmz) (Figure 7) were also investigated.
55
  
 
 
Figure 7.  Structural formula of Schiff base ligands used for catalytic activity.
55
 
Similarly, both complexes exhibited similar catalytic properties when compared to that of 
[VVO2(Sal-aebmz)].
55
 
Extensive research has been carried out on complexes of N-salicylideneamino 
acids, typified by their vanadium compounds.
56-59
 V(IV) and V(V) complexes containing 
Schiff base ligands generally exhibit coordination geometry such as that of compounds 
12 and 13 shown in Figure 8. The formation of dinuclear oxo-bridged V
IV–O–VV or VV–
O–V compounds (such as compound 14 in Figure 8) has also been reported.59-61 When 
methanolic solutions of [V
IV
O(sal–aa)(H2O)] complexes (sal–aa = N-salicylidene-amino 
acidato) were allowed to stand in air, the complexes were spontaneously oxidized to form 
[V
V
O(sal–aa)(OMe)(OHMe)] (13). Similarly, the presence of bpy in solution during 
aerial oxidation, results in the formation of compound 15, formed from the coordination 
of bpy ligand to the [V
IV
O]
2+
 metal center.
59-61
 
Due to their potential pharmacological applications, there is now a growing 
interest in the chemistry of hydrazine and hydrazone compounds.
62
 In the past, 
13 
 
 
 
Figure 8.  Structure of V(IV) and V(V) complexes containing Schiff base ligands.
59
 
great interest has aroused in the mode of chelation of acid hydrazides R-CO-NH-NH2 and 
their corresponding aryolhydrazones R-CO-NH-N=CHR with transition metal ions.
62
 In 
2008, Mishra and Soni reported the synthesis, characterization and biological activity of 
VO(II) and Co(II) complexes synthesized from the reaction of methyl isobutyl ketone 
with nicotinamide (mna)/2-amino-4-chlorophenol (map) and 2-hydroxy acetophenone 
with nicotinamide (han)/isoniazide (hai) (Figure 9).
62
 The Schiff base ligands and the  
 
  
Figure 9.  The structure of Schiff base ligands containing acid hydrazides and 
aryolhydrazones.
62
 
 
14 
 
 
respective VO(II) and Co(II) complexes (Figure 10) were shown to exhibit significant 
antibacterial and antifungal activity.
62
 Chelation was suggested to have a major effect on 
the enhancement or suppression of the biochemical activity since the majority of the 
complexes were observed to be more active than their respective Schiff bases.
62
  
Due to the stability of the quinazoline nucleus, quinazolinones are also an 
excellent reservoir of bioactive substances.
63
 4(3H)-quinazolinones is known to 
 
Figure 10.  Proposed structures of VO(II) and Co(II) complexes containing Schiff base 
ligands.
62
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possess many potential pharmalogical applications.
58,59
 Hence, there is now a 
considerable interest in the chemistry of 4(3H)-quinazolinones.
63,64
 Studies involving 
vanadium chemistry with4-(3H)-quinazolinones ring systems are very scarce in 
literature.
63
 Very recently, Prasad et al.
63
 reported the synthesis of two newly synthesized 
Schiff base ligands (Figure 11), viz., 2-methyl-3-(pyridine-2  
 
Figure 11.  The structure of 4(3H)-quinazolinone Schiff base ligands.
63
 
ylmethyleneamine)quinazolin-4(3H)-one and 3-(4-hydroxy-3-
methoxybenzylideneamino)-2-methylquinazolin-4(3H)-one with 1,10-phenanthroline. 
Biological studies carried out by Prasad et al.
63
 has also demonstrated the ability 
of Schiff base ligands to bind to CT-DNA in intercalative mode.
63
 According to Prasad et 
al.,
63
 oxovanadium(IV) complexes containing the two newly synthesized Schiff base 
ligands (Figure 12), can readily bind to CT-DNA in intercalative mode.
63
 Schiff base 
transition metal complexes are currently used in the design and development of synthetic 
restriction enzymes, foot printing agents, chemotherapeutic agents, site specific cleavers, 
spectroscopic probes, and molecular photo switches.
63
 The interaction of these Schiff 
base-transition metal complexes with nucleic acids is a therefore major area of research 
to medicinal chemists.
63
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Vanadium and Cancer 
Cancer or neoplasia is the term used to define diseases characterized by 
uncontrolled proliferation and the spread of abnormal forms of the body cells.
65
 
 
 
 
 
 
 
 
 
 
 
 Figure 12.  Oxovanadium(IV) complexes containing two synthesized Schiff base ligands 
that can bind to CT-DNA in intercalative mode.
63
 
Neoplastic cells possesses the ability to continually divide and proliferate which leads to 
the formation of localized tumors.
65
 The invasiveness of these cells and the ability to 
metastasize, results in the growth of tumors at secondary sites, which undergoes 
uncontrolled growth and later spreads throughout the entire body leading to starvation 
and death of normal tissue cells.
65
 
Chemotherapeutic cancer treatment involves the use of drugs that are capable of 
selectively targeting rapidly proliferating neoplastic cells (in preference to healthy body 
cells) used in combination with surgery and/or radiation therapy.
66
 An in depth 
17 
 
 
understanding of the mechanism by which the regulation of cell division and proliferation 
is disrupted by neoplastic cells is critical for advances in new cancer treatment.
66
 The 
activity of anticancer drugs is generally exerted by the inhibition of one or more 
processes occurring in the normal cell cycle.
65
  
The study of metal containing antitumor agents began in the year 1969 following 
the detection of the antitumor properties of cisplatin [cis-diamminedichloroplatinum(II)] 
(Figure 13).
67
 Cisplatin is one of the most successful anticancer drugs and is effective in  
 
 
Figure 13.  Structure of cisplatin.
68
 
the treatment of a variety of cancers (with a cure rate greater than 90% in the case of 
testicular cancer).
68-70
 The clinical success of cisplatin as an antitumor agent is limited by 
factors including acquired or intrinsic drug resistance, and the lack of selectivity for 
tumor tissues, which leads to severe side effects including renal impairment, 
neurotoxicity and cytotoxicity.
71,72
 The development of non-platinum metal based drugs 
has received considerable interest and a few of these compounds are currently in 
undergoing clinical studies.
73,74
 A range of metal complexes, such as gold, iron, 
ruthenium, rhodium, palladium, gallium, and tin have demonstrated interesting antitumor  
activity but have not yet entered clinical trial.
75
  
In 1983, English et al.
76
 and Thompson et al.
77
 discovered that vanadium exerted 
an inhibitory effect on the terminal differentiation of murine erythroleukemia cells.
78
  
Dietary administration of ammonium vanadate was shown to inhibit chemically-induced 
18 
 
 
mammary carcinogenesis.
77,78
 Since then, the use of vanadium in the treatment of human 
diseases has been widely investigated.
79-82
 
In 1965, the first discovery of the anticancer effect of vanadium salts were 
reported by Kieler et al.
83
 Since then, several studies have been carried out to determine 
the biochemical and molecular mechanism underlying the antitumor vanadium salts.
7,84,85
  
Vanadium was shown to be effective in the prevention and/or reduction of chemically 
induced preneoplastic and neoplastic development in various target organs.
85
 The 
putative therapeutic effects of vanadium on the growth and metastatic potential of tumor 
cells have also been reported in literature.
85
 
Vanadium compounds are capable of exerting anti-carcinogenic effects in several 
different ways as shown in Figure 14.
7
 Although very few vanadium complexes have 
been tested for antitumor activity, several peroxovanadium and vanadocene complexes 
are known to exert anti-proliferative and proliferative activity on various cell types.
78
 In 
2004, peroxovanadium complexes including potassium bisperoxo(1,10-
phenanthroline)oxovanadate(V) and potassium bisperoxo(pyridine-2-
carboxylato)oxovanadate(V) (Figure 15) were shown to reduce proliferative activity of 
neuroblastoma NB41 and glioma C6 cell lines.
7,86
 The biological effect of vanadium in 
various cell lines were also enhanced by the concomitant treatment of vanadate(IV) and 
peroxide due to the formation of peroxovanadate.
78
  In vitro studies also demonstrated a 
marked increase in protein tyrosine phosphorylation and phosphoinositide breakdown, 
combined with the selective inhibition of protein tyrosine phosphatase and 
phosphotyrosine phosphatase activities.
78
 The inhibitory effect of peroxovanadium  
19 
 
 
complexes is proposed to be 100-1000 times greater than that of sodium orthovanadate in 
vitro.
78
 
Vanadium compounds generally exert their anti-proliferative effects on normal or 
malignant cell lines through cell cycle arrest.
78
 This was demonstrated by Zhang et al.,
88
   
 
 
Figure 14.  Schematic presentation of the actions, through which the antitumor effects of 
vanadium are exerted.
7 
(PTPs - Protein Tyrosine Phospahatases and PTKs - Protein 
Tyrosine Kinases). Reproduced with permission from Crit. Rev. Oncol. Hematol., 2002, 
42, p.255. Copyright 2002 by Elsevier.  
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Figure 15.  Peroxovanadium complexes that exhibit proliferative activity.
87
 
when vanadate was shown to both induce G2/M-phase arrest in p53-deficient mouse 
embryo fibroblasts and promote S-phase entry in the corresponding p53 wild-type 
cells.
78,88
 Anti-proliferative and cytotoxic effects of vanadium compounds may also be 
exerted via interactions with DNA.
7
 Vanadocene complexes, including vanadocene 
dichloride (Figure 16), are known to interact with the phosphate groups of DNA 
nucleotides to form a labile outer sphere complex.
7
  
 
 
Figure 16.  The structure of vanadocene dichloride.
89
 
Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) ([VO(SO4)(Me2-
Phen)2]) (metvan) was also recently identified as an active apoptosis inducing agent with 
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potent in vitro antitumor activity (Figure 17).
79,90-92
 Apoptosis (programmed cell death) is 
characterized by nuclear fragmentation, membrane blebbing, nuclear and cytoplasmic  
condensation, and by the appearance of apoptotic bodies.
7,93
 Metvan induces apoptosis in 
multiple myeloma cell lines, leukemic cell lines, and solid tumor cell lines derived from 
breast cancer, glioblastoma, and testicular cancer patients at nanomolar to low 
micromolar concentrations.
79,90,91
 Metvan is highly effective against cisplatin-resistant 
ovarian and testicular cancer cell lines and represents the first vanadium complex as a 
 
 
Figure 17.  Structure of Metvan.
144
 
possible alternative to platinum-based chemotherapy.
94
 Metvan induced apoptosis is 
mediated by the depolarization of mitochondrial membranes, the depletion of glutathione, 
and the generation of reactive oxygen species.
79,94
 
Thiosemicarbazone Ligands and Metal Complexes 
Thiosemicarbazones are a very unique class of compounds due to their 
pharmacological applications and their versatility in coordination chemistry.
95
 
Thiosemicarbazones and their metal complexes have long been recognized for their 
potential antiviral, antibacterial, antifungal, antimalarial, and antitumor activities.
96-100
 
Thiosemicarbazones are versatile mixed hard-soft oxygen/nitrogen-sulfur chelating 
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ligands, exhibiting various binding modes with transition and some main group 
metals.
101,102
 The presence of amide, thione and imine groups makes them potential 
polydentate ligands.
103
  
Thiosemicarbazones usually coordinate to metal centers in a bidentate mode via 
the imine nitrogen and the sulfur atom of the thioamide moiety. The coordination mode 
can be increased however by the incorporation of an additional donor groups as  
heterocyclic substituents.
95
 The most common donor set involves the ONS or NNS atoms 
in which one or two ligands are attached to the metal center, which is bridged through 
either thiolate sulfur or a non-thiosemicarbazone coligand (i.e.N3, Cl, NCS, CH3COO, 
etc.).
95,104
 Depending on the disposition of substituents about the imine and thioamide 
groups, -pyridyl thiosemicarbzones are known to exist in three isomeric forms (Figure 
18).
105
 Intramolecular hydrogen bonding plays a very important role in the structural 
determination of the isomeric forms of thiosemicarbazones.
105
  
 As reported in literature, the anticancer activity of thiosemicarbazone metal 
derivatives is much more effective than that of the free ligand.
95
 This is due to the change 
in the binding affinity of metals to proteins and enzymes that occur following the 
coordination of a thiosemicarbazone ligand to a metal center.
95
 This results in a change in 
the interaction of the respective complex with DNA thereby causing an effect on DNA 
replication and cell proliferation.
95
 
Following the discovery of the antileukemic activity2-formylpyridine 
thiosemicarbazone (Figure 19) in the 1950s, the antineoplastic activity of -N- 
heterocyclic thiosemicarbazones has since been thoroughly investigated.
106
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Figure 18.  Isomeric forms of -pyridyl thiosemicarbzones showing Z, E (anti, anti) and 
E’ (syn,syn) isomeric forms.105 
 
 
Figure 19.  Structure of 2-formylpyridine thiosemicarbazone.
105
 
Several reports have recently documented the preparation and biological activity of 
transition metal complexes containing thiosemicarbazone ligands.
105
 Ribonucleotide 
reductase (RR) (a mammalian enzyme) has been identified as a principal target for 
thiosemicarbazones.
102,107
 In 1961, Peter Reichard reported the discovery of the enzyme 
RR in E. coli.
108,109
 This enzyme was later found in all growing cells of every living 
organism and in several species of viruses.
108,110
 
Thiosemicarbazones are the strongest known inhibitor of RR both in cell-free 
assay and in intact tumor cells.
101
 The inhibition of RR is results in the pronounced 
antineoplastic efficacy of thiosemicarbazones.
105,111
 RR catalyzes the reductive 
conversion of ribonucleotides to deoxyribonucleotides, which is a crucial, rate-limiting 
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step in the pathway leading to the biosynthesis of DNA.
112
 The reaction involves the 
replacement of the C2’-hydroxyl group on the ribose moiety by a hydrogen atom 
(Scheme 4).
108
 
 
 
Scheme 4.  Ribonucleotide reduction catalysed by ribonucleotide reductase.
108
 
RR is produced at the transition from G1 to the S phase of the cell cycle as a 
prerequisite for DNA replication and is highly active in proliferating tumor cells, making 
it an excellent target for tumor chemotherapy.
101,113
 Mammalian (class 1a) RR consists of 
two non-identical subunits called R1 ( 2 homodimer) and R2 ( 2 homodimer).
101
 The R1 
subunit harbors the catalytically active center consisting of redox active cysteines 
regenerated by the action of thioredoxin.
101
 The R2 subunit contains a tyrosyl radical and 
a diiron center, both of which are essential for the initiation of the reductive process at the 
active site in R1.
101,114
   
RR inhibitors are divided into four classes depending on the mode of action: 
radical scavengers, chelating molecules, and nucleoside analogs.
101
 The inhibitory effect 
of thiosemicarbazone is often attributed to their pronounced iron-chelating 
properties.
101,107
 The chelation of iron from the R2 subunit of the enzyme, results in the 
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formation of an active iron complex, which is responsible for the inhibition of the RR 
enzyme.
101,107
 
The ability of thiosemicarbazones to chelate metal ions is solely dependent on the 
presence of a N,N,S tridentate “soft donor” coordination system, which allows for the 
coordination of iron, copper, zinc and several other transition metals.
105,111
 The antitumor 
activity of thiosemicarbazones is therefore assumed to originate from the capability of 
these compounds to form stable metal complexes.
115
 According to Thelander and 
Graslund,
116
 the existence of an active iron complex confirms the proposed mechanism, 
which involves the reduction of an iron(III) complex (containing 1-formylisoquinoline 
thiosemicarbazone) to form a stable iron(II) complex (in the presence of dithioreitol).
116
 
Presently, gemcitabine and hydroxyurea (HU) (Figure 20) are the only known 
clinically approved inhibitors of RR.
112,117,118
 Recently, Sartorelli and coworkers also  
reported the synthesis and biological evaluation of 3-aminopyridine-2-carboxaldehyde 
thiosemicarbazone (3-AP) and 3-aminopyridine-4-methyl-2-carboxyaldehyde 
thiosemicarbazone (3-AMP) (Figure 21).
119
 3-AP (triapine) is the first reported 
thiosemicarbazone to enter phase II clinical trials as an antineoplastic agent.
102
 A 
comparative study of 3-AP and HU demonstrated a greater inhibitory potency for 3-AP 
against L1210 leukemia cells, both in vitro and in vivo.
105,120,121
 3-AP was also observed 
to be active against HU-resistant cells.
105,120
 This observation lead to the suggestion of 
other possible modes of action, which may include radical reactions or inhibition of 
topoisomerase II.
101 
The high general toxicity and the consequent low therapeutic index are the major 
disadvantages associated with the use of thiosemicarbazones as antineoplastic agents.
101
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Figure 20.  Structure of gemcitabine and hydroxyurea. 
112,117,118
 
 
 
Figure 21.  Structure of 3-AP and 3-AMP.
119
   
The entry of 3-AP into clinical stages, however, has led to a renewed interest in the 
antineoplastic effects of thiosemicarbazone complexes.
101
 Recently, the biological 
activity of several metal complexes containing -pyridyl and salicyladehyde (and their 
analogues) thiosemicarbazones (Figure 22) have been reported in literature.
101,105
 
Gallium(III) complexes has been reported to possess clinically useful antipoliferative 
properties.
122,123
 The synthesis of a series of gallium(III) and iron(III) complexes with N-
substituted -N-heterocyclic thiosemicarbazones were recently reported by Kowol et al 
(Figure 23).
122
 The ligand binding affinity of gallium(III) is very similar to that of 
iron(III), which often leads to an upset in the availability of intracellular iron.
122
 Gallium 
interacts directly with RR and competes with iron for the binding site in the R2 unit of 
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Figure 22.  Structure of the -Pyridyl Thiosemicarbazone, Salicylaldehde 
Thiosemicrbazone, and Benzaldehyde/Benzophenone Thiosemicarbazone Metal 
Complexes.
105
 
 
the enzyme.
122,124,125
  
Pronounced differences in the cytotoxic effect were observed upon variation in 
the central metal ion.
101
 Gallium(III) was shown to enhance cytotoxicity due to the 
synergistic action of the two components.
101
  The complexation to iron(III), however, 
 
Figure 23.  Structure of thiosemicarbazones and their gallium(III) and iron(III) 
complexes.
122
 
 
resulted in a marked attenuation of the antiproliferative activity.
101
 The design of metal 
complexes in which both the metal and the ligand is directed at the same molecular target 
produces highly potent RR inhibitors due to the synergistic action of the two 
components.
122
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The antimicrobial and DNA cleavage activity of a series of Co(II), Ni(II), and 
Cu(II) complexes with Schiff bases derived from m-chloro/nitro substituted 
thiosemicarbazides and 2-methoxy benzaldehyde (possessing sulfur and azomethine 
nitrogen donors) (Figure 24) were reported by Patil et al.
126
 Although a significant  
 
 
Figure 24.  Structure of Co(II), Ni(II), and Cu(II) complexes containing 
thiosemicarbazone ligands.
126
 
 
increase in activity was observed upon coordination, both the Schiff base ligands and 
their metal complexes were shown to be highly active against some of the antifungal and 
antibacterial species.
126
 
Ruthenium complexes are believed to have low toxicity and good selectivity for 
tumors.
127,128
 As such, ruthenium complexes are widely studied as metallodrugs.
127,128
 
Ruthenium has been reported to possess several favorable anticancer properties and 
several of these ruthenium containing complexes are known to interaction with DNA and 
RNA causing a reduction in tumor growth.
129-131
 Imidazolium trans-[tetrachlorido(1H-
imidazole)-(S-dimethyl sulfoxide)ruthenate(III)] (NAMI-A) and indazolium trans-
[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) (Figure 25)  are two of the most 
promising ruthenium based complexes for clinical use as anticancer agents.
132
 Both 
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NAMI-A and KP1019 have successfully completed phase 1 clinical trials and are 
currently undergoing phase II studies.
132
 NAMI-A is known to exert an inhibitory effect 
 
Figure 25.  Structure of NAMI-A and KP1019.
132
 
 on metastases formation and causes a reduction in the weight of  metastasis without 
affecting the primary tumor.
133
 The application of KP1019, however,  is mainly aimed at 
the treatment of solid tumors such as colorectal carcinoma.
133
 
Several researchers have demonstrated interest in the possibility of identifying a 
new anticancer drug among ruthenium complexes containing thiosemicarbazone 
ligands.
134,135
 Recently, the cytotoxicity of a series of mixed-ligand diimine ruthenium 
complexes of the type [(bipy)2Ru(TSC)](PF6)2 and [(phen)2Ru(TSC)](PF6)2 (Figure 26) 
was reported by Beckford et al.
128
 All complexes were observed to interact with DNA via  
weak to moderate intercalation, and they all showed good cytotoxicity against a variety of 
human cancer cell lines including MCF-7 and MDA-MB-231 (breast adenocarcinoma) 
and HCT 116 and HT-29 (colorectal carcinoma) cell lines.
128
 
In 2006, the synthesis, characterization and antiamoebic properties of several 
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Figure 26.  Ruthenium(II) complexes containing thiosemicarbazone ligands.
128
 
neutral dioxovanadium(V) complexes [VO2(HL)] (H2L = I: 24, H2L = II: 25 and H2L = 
III: 26; H2L are the thiosemicarbazones H2pydx-tsc (I), H2pydx-chtsc (II) and H2pydx-
clbtsc (III); pydx = pyridoxal, tsc = thiosemicarbazide, chtsc = N4-
cyclohexylthiosemicarbazide, clbtsc = N4-(2-chloro)benzylthiosemicarbazide) (Figure 
27) were reported by Maurya et al.
136
 Upon heating, methanolic solutions of these 
complexes readily dimerized to form the respective -oxo binuclear complexes 
[(VOL)2  -O] (H2L = I: 27, H2L = II: 28, H2L = III: 29) as shown in Figure 27.
136
 
 
 
 
Figure 27.  Structure of neutral dioxovanadium(V) complexes containing 
thiosemicarbazone ligands.
136
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Research Aim 
 
The main aim of this project is to synthesize, characterize and investigate the anti-
proliferative properties of a series of novel V(IV) compounds containing 
thiosemicarbzone ligands.  In this study, three thiosemicarbazone ligands will be 
synthesized. The three thiosemicarbazone ligands will then be coordinated to [VO(Sal-L-
tryp)(H2O)] (1), to produce  three novel V(IV)-containing complexes. All ligands and 
complexes will be characterized using electrochemical and several spectroscopic 
techniques.  
Preliminary in vitro studies will also be carried out in order to investigate the anti-
proliferative activity of the novel compounds. In vitro studies will be carried out using 
colon cancer cell lines, and the results obtained will be compared with that of normal 
non-cancerous colonic myofibroblasts.   These compounds are proposed to have the 
potential to be used as anticancer agents. Stability studies in DMSO solvent to ascertain 
the oxidation numbers of the vanadium-containing species.  Spectroscopic techniques will 
be used in order to determine the identity of the products formed upon aerial oxidation in 
DMSO. The hypotheses are as follows: 
 Vanadium(IV) complexes are resistant to aerial oxidation. 
 Vanadium(IV) complexes do exhibit anti-proliferative properties against 
colon cancer cell lines.  
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CHAPTER II 
EXPERIMENTAL 
Materials 
 Analytical or reagent grade chemicals were used throughout this study. All  
reagents and solvents were obtained from Sigma-Aldrich (St. Louis, MO, USA) or 
other commercial vendors, and used as received.  
Instrumentation and Techniques 
 Microanalyses (C, H, N) were performed by Desert Analytics, Tucson, U.S.A. 
and Columbia Analytical Services, 3860 S. Palo Verde Road Suite 303, Tucson, AZ 
85714, U.S.A. All FT IR spectra were acquired on a Nicolet 6700 FT IR 
spectrophotometer in the range 4000-400 cm
-1
 using the ATR accessory (with a 
diamond crystal). 
1
H- and 
13
C-NMR spectra were acquired in DMSO-d6 on a Bruker 
400 MHz spectrometer operating at ambient temperature. The residual 
1
H- and 
13
C- 
present in DMSO-d6 (2.49 and 39.7 ppm, respectively) were used as internal 
references. Electronic absorption spectra were recorded on a HP8452 diode array 
spectrophotometer using quartz cuvettes and DMSO as the solvent. Fluorescence 
spectra were acquired on a Cary Eclipse fluorescence spectrophotometer (Varian Inc.) 
using a slit width of 10 nm.   
Electrospray Ionization Mass Spectrometry (ESI MS) 
 ESI MS data was collected on an HP Agilent 1956b single-quadrupole mass 
spectrometer. Samples were dissolved in an acetic acid/methanol mixture and 
introduced by direct injection using a syringe pump at a flow rate of 100 L s
-1
 while 
sweeping the cone voltage from 0 to 200 V at a rate of 10 V min
-1
. All m/z ratios and 
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percentages presented as ESI MS data were determined using the MestReNova 
software. 
Electrochemical Studies 
  Cyclic voltammetric (CV) and square wave (SQW) data were collected on a 
Bioanalytical Systems Inc. Episilon workstation on a C3 cell stand at 296 K. 
Measurements were carried out using a three-electrode system consisting of a 1.6 mm 
platinum working electrode, a platinum wire auxiliary electrode, and a Ag/Ag
+
 (0.01 
M AgNO3 and 0.10 M TBAP in acetonitrile) reference electrode. The working 
electrode was polished before each experiment with alumina slurry.  DMSO solutions 
(1.0 mM) containing 0.10 M tetra-n-butylammonium hexafluorophosphate (TBAP) as 
supporting electrolyte were saturated with argon for 15 minutes prior to each run. A 
blanket of argon gas was maintained throughout the measurements and ferrocene was 
used as an internal standard (E1/2 = 0.09 V versus Ag/Ag
+
).  
X-ray Crystallography 
  X-ray crystallographic data collection, structure analysis and refinement, and 
intensity data of the acetylethTSC were obtained by Dr. Don VanDerveer and Dr. 
Frank R. Fronczek of Clemson University and Louisiana State University, 
respectively. Crystallographic data were collected at 90 K on a Bruker Kappa Apex-II 
CCD diffractometer equipped with CuK  radiation and an Oxford Cryosystems 
Cryostream cooler.  The structure of acetylethTSC was solved using SHELXS
137
 and 
refined using the SHELX97
138,139
 software packages. All H atoms were visible in 
difference maps. Coordinates of the NH hydrogen atoms were refined individually 
while those on C were placed in idealized positions with torsional parameters refined 
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for the methyl groups. Crystal data: C8H12N4S2, FW = 228.34, monoclinic, space 
group = C2/c, a =10.4549(10), b = 10.8970(10), c = 18.7694(15) Å, β = 91.544(5)º, V 
=  2137.6(3) Å
3, Z = 8, T = 90.0(5)K, μ = 4.25 mm-1, dcalc = 1.419 g cm
−3
, colourless 
parallelepiped, dimensions = 0.18 x 0.17 x 0.09 mm, reflections collected = 8017, 
unique reflections = 1901, observed reflections (I > 2σ(I)) = 1738, Rint = 0.026, No. of 
parameters = 136, R1 = 0.028, R2 = 0.069, GOF(F
2
) = 1.065, CCDC No. = 812348. 
Cell Culture 
 
  All in vitro studies were done by Dr. Antonio González-Sarrías of the 
University of Rhode Island. All cell lines were obtained from the American Type 
Culture Collection (ATCC, Rockville, MD, U.S.A.) and maintained at the University 
of Rhode Island, U.S.A. Cell lines used included three human colon cancer cells: 
HCT116 (human colon carcinoma), HT-29 (human colon adenocarcinoma) and Caco-
2 (human epithelial colorectal adenocarcinoma).  Non-cancerous human colon cells, 
CCD-18Co (human colon fibroblasts) were also used in this study.  Caco-2 cells were 
grown in EMEM medium supplemented with 10% v/v fetal bovine serum, 1% v/v L-
glutamine, 1% v/v nonessential amino acids, and 1% v/v antibiotic solution (Sigma-
Aldrich). HT-29 and HCT-116 cells were grown in McCoy’s 5a medium 
supplemented with 10% v/v fetal bovine serum, 1% v/v non-essential amino acids, 
2% v/v HEPES and 1% v/v antibiotic solution. CCD-18Co cells were grown in 
EMEM medium supplemented with 10% v/v fetal bovine serum, 1% v/v non-essential 
amino acids, 1% v/v L-glutamine, and 1% v/v antibiotic solution and were used from 
PDL = 26 to PDL = 35 for all experiments. Cells were maintained in an incubator at 
37 ºC under an atmosphere of 5% CO2/95% air atmosphere at constant humidity and 
maintained in the linear phase of growth. The pH of the culture medium inside the 
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incubator was determined using pH indicator paper (pHydrionTM Brilliant, pH 5.5-
9.0, Micro Essential Laboratory, NY, U.S.A.). Prior to addition to the culture mixture, 
all test samples were dissolved in DMSO (<0.5 % in the culture medium) by 
sonication and then filter sterilised (0.2 μm). Control cells were also carried out in 
parallel sequences and subjected to the same changes in medium with a 0.5 % DMSO.  
Cytotoxicity Assay 
  This assay was carried out as described by Cory et at.
140
 in order to measure 
the IC50 values for samples. The in vitro cytotoxicity of samples were briefly assessed 
in tumour cells by a tetrazolium-based colorimetric assay taking advantage of the 
metabolic conversion of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-tetrazolium, inner salt] to a reduced form 
that absorbs light at 490 nm.  Cells were counted using a hemacytometer and were 
plated at 2000-5,000 cells per well, depending on the cell line, in a 96-well format for 
24 hours prior to drug addition. All test samples and a positive control, etoposide 4 
mg ml
-1
 (Sigma-Aldrich), were dissolved in DMSO (by sonication) and diluted with 
media to the desired treatment concentration and the final DMSO concentration per 
well did not exceed 0.5%.  Control wells were also included on all plates . Following a 
24, 48, or 72 hour drug-incubation period of the serially diluted test compounds at 37 
C, MTS, in combination with the electron coupling agent, phenazine methosulphate, 
was added to the wells and cells were incubated at 37 ˚C in a humidified incubator for 
three hours. Absorbances at 490 nm (OD490) were acquired on a spectrophotometer 
(SpectraMax M2, Molecular Devices Corp., operated by SoftmaxPro v.4.6 software, 
Sunnyvale, CA, U.S.A.) to obtain the number of surviving cells relative to control 
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populations. The results are expressed as the median cytotoxic concentrations (IC 50 
values) and were calculated from six-point dose response curves using 4-fold serial 
dilutions. Each point on the curve was tested in.  Data are expressed as mean  SE for 
three replications on each cell line. 
Synthesis of Ligands 
 9-anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC) was prepared by 
Dr. Floyd Beckford of Lyon College.
128
  
N-Ethhymethohcarbthio. This ligand was initially synthesized by Dr. Floyd 
Beckford and Dr. Ramaiyer Venkatraman. This synthesis reproduced during the 
course of this research project. 4-ethyl-3-thiosemicarbazide (2.35 g, 19.7 mmol)  and 
o-Vanillin (3.00 g, 19.7 mmol)  were placed in a 250 mL round bottom flask followed 
by absolute ethanol (100 mL). Approximately 10 drops of glacial acetic acid were 
added to the off-white suspension, and the reaction mixture was heated to reflux 
solvent for three hours. The reaction mixture was then cooled to room temperature 
and filtered through a sinistered glass crucible. The white solid obtained was washed 
with ethanol (3 x15 mL) followed by ether (3 x10 mL) and allowed to air dry. Yield = 
4.97 g (99%).   The purity was checked by elemental analysis. Calc. for C10H13N3O2S: 
C, 52.15; H, 5.97; N, 16.59. Found: C, 52.53; H, 6.16; N, 17.02; Infrared spectrum 
( /cm
-1
): FT IR ( /cm
-1
): 3304 (m) (-N
1
H), 3300 (m) (-N
2
H), 3130 (br) (OH), 1155 
(m) (N-N), 1606 (m) (TSC (C=N)), (1267) (m) and (831) (m) (C=S). H (400 MHz; 
DMSO-d6); 1.15 (t) (3H) (-CH3), 3.46 (s) (1H) (-CH3-OAr), 3.60 (q) (2H) (CH2), 7.57 
(s) (1H) (azomethine -CH=N), 6.78 (t) (CHar), 6.94 (dd) (CHar), 8.43 (s) (3H) (aminic 
NH), 9.19 (s) (1H) (ArOH), 11.42 (s) (1H) (hydrazinic-NH); 
13
C (400 MHz; DMSO-
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d6);  172.90 (C=S), 165.73 (CH=N), 163.26 (-COCH3ar), 136.21 (ROH), 120.61 
(CCH=Nar), 118.31 (CHar), 118.04 (CHar), 111.57 (CHar), 56.02 (OCH3), 29.95 (CH2), 
15.06 (CH3). 
AcetylethTSC. AcetylethTSC was synthesized and characterized by Dr. 
Ramaiyer Venkatraman from Jackson State University.  This synthesis was also 
repeated during the course of this research project. 2-Acetylthiazole (0.636 g, 0.518 
ml 5.0 mmol) was placed in a 100 ml round bottomed flask followed by anhydrous 
methanol (25 mL). 4-Ethyl-3-thiocarbazide (0.596 g, 5.0 mmol) in anhydrous 
methanol (25 mL) was slowly added to the solution of 2-acetylthiazole follwed by a 
few drops of concentrated hydrochloric acid.  The reaction mixture was stirred and 
heated to reflux solvent for two hours, then evaporated to a minimum volume to form 
a yellow solid.  The mixture was filtered and the residue was washed with ether and 
air-dried. Yield = 0.750 g (66%). A single cystal for X-ray crystallography was grown 
by slow evaporation from methanol.  FT IR ( /cm
-1
): 3164 (m) (-N
1
H), 3054 (m) (-
N
2
H), 1059 (m) (N-N), 1543 (m) (TSC (C=N)), (1296) (m) and (813) (m) (C=S). H 
(400 MHz; DMSO-d6); 1.16 (t) (3H) (-CH3), 2.42 (s) (3H) (CH3CH=N), 3.61 (d) (2H) 
(CH2), 7.39 (d) (CHar), 7.89 (d) (CHar), 8.34 (s) (3H) (aminic NH), 10.61 (s) (1H) 
(hydrazinic-NH). 
Reduced Schiff base (2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic 
acid). The reduced Schiff  base was prepared using a known procedure involving 
salicylaldehyde, amino acids, and NaBH4, but with L-trptophan using the following 
synthetic procedure:
141
  L-tryptophan (2.042 g, 10.0 mmol) and potassium hydroxide 
(0.56 g, 10.0 mmol) were added to a 125 mL Erlenmeyer flask, followed by deionised 
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water (10 mL). Salicylaldehyde (1.029 mL, 10.0 mmol) in absolute ethanol (10 mL) 
was slowly added to the mixture. The yellow solution was then stirred for thirty 
minutes prior to cooling in an ice bath. The intermediate Schiff base formed in situ 
was then reduced with an excess  of sodium borohydride (0.46 g, 12 mmol) in water 
(5 mL) containing 10 drops of 2 M sodium hydroxide. The solution was stirred for ten 
minutes,  and the yellow color slowly discharged. The solution was then acified with 
concentrated HCl to  pH 4.68 and the resulting solid was filtered off, washed with 
ethanol (2 x 30 mL) and diethyl ether (2 x 30 mL), and dried. The white solid 
obtained was recrystalized twice from water/ethanol (1:1). Yield = 1.08 g (35%). m/z 
(ESI) (+ve mode) 311.08 (100.00%, [M+H]
+
), 242.42 (13.04%, [M-CHO3 + H]
+
), 
620.36 (12.77%, [2M + H]
+
), 930.39 (5.02%, [3M+H]
+
), 1240.92 (3.92%, [4M + H]
+
). 
FT IR ( /cm
-1
): 3392 (m) (indolic NH), 3055 (br) (OH), 1208 (m) (C-O)), 1494 (m) 
(COOs) and 1592 (m) (COOas). H (400 MHz; DMSO-d6); 2.67 (d) (2H) (H (j)), 3.21 
(d) (2H) ((H (h)), 3.05 (d) (2H) (H (g)), 5.91 (t) (1H) (H (d)), 6.15 (d) (1H) (H (b)), 
6.31 (d) (1H) (H (l)), 6.62 (m) (1H) (H (n)), 6.62 (m) (1H) (H (o)), 6.62 (m) (1H) (H 
(p)), 6.62 (m) (1H) (H (q)), 6.90 (d) (1H) (H (a)) and 7.18 (d) (1H) (H (c));
 13
C (400 
MHz; DMSO-d6);  28.57 (C (j)), 46.72 (C (g)), 63.61 (C (h)), 110.66 (C (n)), 111.57 
(C (k)), 113.46 (C (d)), 118.50 (C (o)), 118.69 (C (q)), 121.37 (C (b)), 123.85 (C (p)), 
123.89 (C (l)), 126.95 (C (f)), 127.78 (C (c)), 128.16 (C (a)), 128.34 (C (r)), 135.97 
(C (m)), 164.55 (C (e)), 182.05 (C (i)). 
K[(Sal-L-tryp)]. This complex was prepared using an analogous synthesis as 
reported by Vanco et al.,
142
 but in our case, L-tryptophan was used instead of -
alanine. To a mixture of L-tryptophan (3.07 g, 15.0 mmol) and potassium hydroxide 
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(0.85 g, 15.0 mmol) dissolved in water (5 mL), the solution of salicylaldehyde (1.57 
mL, 15.0 mmol) in 10 mL of ethanol was added with stirring. The resulting yellow 
solution was stirred at room temperature for 24 hours, and then, it was diluted by 
ethanol (25 mL). Upon slow evaporation of solvent, a yellow oil was formed, which 
was then tertuated with diethyl ether. Solution was then filtered and dried under 
vacuum to give a yellow powder. Yield =  4.85 g (93%). m/z (ESI) (+ve mode) 344.05 
(39.65%, [M + H]
+
), 300.03 (100.00%, [M - OH - K + H]
+
), 281.14 (46.08%, [M - 
OH - O - K + H]
+
), 262.12 (1.51%, [M - COO - K + H]
+
), 242.62 (64.65%, [M - COO 
- OH - K + H]
+
) and 205.20 (50.43%, [M - C7H6O - K + H]
+
). FT IR ( /cm
-1
): 3407 
(m) (indolic NH), 3169 (br) (OH), 1194 (m) (C-O)), 1521 (m) (COOs), 1604 (m) 
(COOas) and 1570 (m) (TSC (C=N)). H (400 MHz; DMSO-d6); 3.13 (t) (2H) (H (k)), 
3.62 (d) (1H) ((H (i)), 4.07 (s) (1H) (H (g)), 6.59 (s) (1H) (H (t)), 6.72 - 7.06 (m) (1H) 
(H (b)), 6.72 - 7.06 (m) (1H) (H (d)), 7.20 (s) (1H) (H (n)), 7.20 (m) (1H) (H (o)), 
7.20 (m) (1H) (H (p)), 7.20 (m) (1H) (H (q)), 7.35 - 7.58 (m) (1H) (H (c)), 7.35 - 7.58 
(m) (1H) (H (e)) and 11.17 (s) (1H) (H (s)); 
13
C (400 MHz; DMSO-d6);  30.16 (C 
(k)), 64.82 (C (i)), 72.43 (C (q)), 111.39 (C (l)), 111.56 (C (p)), 115.74 (C (b)), 
117.62 (C (d)), 117.99 (C (n)), 118.31 (C (t)), 118.33 (C (f)), 120.59 (C (o)), 123.38 
(C (m)), 127.36 (C (c)), 131.77 (C (r)), 132.01 (C (e)), 163.27 (C (a)) and 172.88 (C 
(j)). 
Synthesis of Complexes 
 [Zn(Sal-L-tryp)(H2O)].0.25 H2O. [Zn(Sal-L-tryp)(H2O)].0.25H2O was prepared 
as by Garcia-Raso et.al. with minor modifications to the general procedure.
143
 L-
tryptophan (5 mmol, 1.024 g) and absolute ethanol (10 mL) was placed in a 250 mL 
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round bottomed flask and the mixture was heated and stirred at 60-70 ˚C. Salicylaldehyde 
(5 mmol, 0.52 mL) in absolute ethanol (10 mL) was slowly added to the mixture. The 
resulting yellow solution was stirred vigorously on a magnetic stirrer for 30 minutes and 
an aqueous solution of zinc(II) acetate dihydrate (5 mmol, 1.098 g) in water (30 mL) was 
added dropwise to the solution. The solution was simultaneous neutralized to pH 7 with 
0.5 M KOH. The resulting solution was stirred for 1 h and the yellow precipitate formed 
was filtered, washed with water, and dried under vacuum. The resulting solid was 
crystallized from methanol and rotary evaporated to dryness. Yield: 1.2608g (64%). m/z 
(ESI) (+ve mode) 395.11 (13.93%, [M + H]
+
) and 1152.92 (92.74%, [Zn3O2(Sal-L-tryp)3 
+ H]
+
). FT IR ( /cm
-1
): 3405 (m) (indolic NH), 3256 (br) (OH), 1551 (m) (C-O)), 1473 
(m) (COOs), 1597 (m) (COOas) and 1581 (m) (TSC (C=N)). H (400 MHz; DMSO-d6); 
4.15 (d) (1H) (H (b)), 7.13 (m) (1H) ((H (c)), 7.06 (t) (1H) (H (d)), 7.34 (d) (1H) (H (e)), 
7.25 (s) (1H) (H (g)), 3.90 (d) (1H) (H (i)), 3.19 (d) (2H) (H (j)), 6.62 (m) (1H) (H (n)), 
6.62 (m) (1H) (H (o)), 6.62 (m) (1H) (H (p)), 10.70 (s) (1H) (H (r))  and 6.62 (m) (1H) (H 
(q)); 
13
C (400 MHz; DMSO-d6);  30.64 (C (j)), 48.66 (C (i)), 69.07 (C (k)), 109.58 (C 
(p)), 111.42 (C (d)), 118.28 (C (m)), 118.28 (C (n)), 118.44 (C (f)), 118.86 (C (o)), 
120.90 (C (b)), 122.22 (C (l)), 124.44 (C (s)), 127.05 (C (c)), 132.87 (C (e)), 134.50 (C 
(q)), 136.19 (C (g)), 167.14 (C (a)) and 179.60 (C (h)). 
[VO(Sal-L-tryp)(H2O)] 1. This complex was prepared as by Costa Pessoa et 
al.
144
 L-tryptophan (1.14 g, 5.60 mmol) and sodium acetate trihydrate (1.47 g, 10.8 
mmol) was placed in a 250 mL round bottomed flask with deionized water (100 mL). 
The mixture was stirred and heated at 50 ˚C to completely dissolve the L-tryptophan. 
Salicylaldehyde (0.59 mL, 5.6 mmol) in absolute ethanol (14 mL) was slowly added 
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to the mixture. The resulting yellow solution was stirred vigorously on a magnetic 
stirrer and an aqueous solution of VOSO4.xH2O (0.78 g, 4.8 mmol) in water (2 mL) 
was added dropwise to the solution. The solution was stirred for 30 minutes. A deep 
dark brown precipitation developed immediately, and then, a heavy precipitation was 
observed. The resulting solution was then filtered under vacuum. The grey solid 
formed was washed with water (30 mL) followed by a ethanol-water mixture (50:50) 
(30 mL) and dried. Yield = 1.19 g (63%). The purity was checked by elemental 
analysis. Calc. for C18H16N2O5V: C, 55.25; H, 4.12; N, 7.16. Found: C, 55.16; H, 
4.31; N, 6.87 (lit.
144
 Calc. for C18H16N2O5V: C, 55.25; H, 4.12; N, 7.16. Found: C, 
55.2; H, 4.2; N, 7.1). FT IR ( /cm
-1
): 3478 (m) (indolic NH), 3014 (br) (OH), 1540 
(m) (C-O), 1490 (m) (COOs), 1597 (m) (COOas), 1600 (m) ([(Sal-L-tryp)] C=N), and 
997 (s) (V=O) (lit.
144
 3480 (m) (indolic NH), 3065 (br) (OH), 1630 (m) ([(Sal-L-tryp)] 
(C=N)), 1600 (m) (C-O)) and 970 (s) (V=O)). UV-Visible spectrum (MeOH), 
λmax./nm ( /M
-1 
cm
-1
): 558 (44) and 758 (27); (lit.
144
   UV-Visible spectrum (DMSO), 
λmax./nm ( /M
-1 
cm
-1
): 275 (15400) and 375 (4850), 520 (45) and 730 (20)). 
Compounds 2-4 were initially synthesized by Mr. Anthony Magnusen. However, 
during this research project, the following syntheses were reproduced to give higher 
purity and improved yields. Compounds were also fully characterized for the first 
time. 
[VO(Sal-L-tryp)(MeATSC)].1.5C2H5OH 2. A 250 mL round bottom flask was 
thoroughly dried; then, (E)-2-(anthracen-9-ylmethylene)-N-
methylhydrazinecarbothioamide (0.15 g, 0.51 mmol) and [VO(Sal-L-tryp)(H2O)] 
(0.20 g, 0.51 mmol) were placed in the 250 mL round bottom flask. Absolute ethanol 
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(100 mL) was added to the flask and the solution was heated to reflux solvent while      
stirring under argon for two hours in an oil bath at 110
 ˚C. An orange-blue solution, 
which was produced, was then rotary evaporated to dryness. Diethyl ether was added 
to the product and the mixture was filtered under vacuum and dried. A green solid 
was collected. Yield = 0.23 g (68%). The purity was checked by elemental analysis. 
Calc. for C38H38N5O5.5 SV: C, 62.03; H, 5.21; N, 9.52. Found: C, 62.62; H, 5.25; N, 
9.33. m/z (ESI) 666.17 (100.00%, [M + H]
+
), 577.08 (33.10%, [[M - C2H5N2S] + H]
+
, 
405.14 (31.86%, [[M - C17H17N3] + H]
+
), 292.14 (54.60%, [MeATSC + H]
+
). FT IR 
( /cm
-1
): 3308 (m) ( indolic NH), 3340 (m) (-N
1
H), 2976 (m) (-N
2
H), 1148 (m) (N-
N), 1544 (m) (C-O)), 1491 (m) (COOs), 1600 (s) (COOas), 1624 (m) (TSC (C=N)), 
1590 (m) ([(Sal-L-tryp)] (C=N)), (1225) (m), (829) (m) (C=S), (455) (m) (V-S), and 
980 (s) (V=O). UV-Visible spectrum (DMSO), λmax./nm ( /M
-1
cm
-1
): 226 (74835), 
292 (sh) (17954), 316 (sh) (10046), 388 (15013), 550 (54), 592 (sh) (45), 756 (28).  
[VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O 3. A 250 mL round bottom 
flask was thoroughly dried; then, (E)-2-(4-hydroxy-3-methoxybenzylidene)-N 
methylhydrazinecarbothioamide (0.065 g, 0.26 mmol) and [VO(Sal-L-tryp)(H2O)] 
(0.10 g, 0.26 mmol) were placed in the 250 mL round bottom flask. Absolute ethanol 
(40 mL) was added to the flask and the solution was refluxed with stirring under 
argon for two hours in an oil bath at 110
 ˚C to form a blue-green solution. The blue-
green solution was rotary evaporated to dryness; then, diethyl ether was added to the 
product and the mixture was filtered under vacuum and dried. Yield = 0.12 g 
(78%).The purity was checked by elemental analysis. Calc. for C29H30N4O7 SV: C, 
53.33; H, 4.64; N, 11.11. Found: C, 53.18; H, 5.21; N, 11.09.  m/z (ESI) 624.87 
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(100.00%, [M - H]
-
), 431.90 (64.75%, [M - C11H10N2O - H]
-
), 407.85 (20.99%, [M -  
C11H15N3O2S - H]
-
), 287.88 (12.70%, [[C11H15N3O2S – C8H7N] - H]
-
), 252.00 
(25.74%, [N-Ethhymethohcarbthio - H]
-
). FT IR ( /cm
-1
): 3210 (m) ( indolic NH), 
3306 (m) (-N
1
H), 2970 (m) (-N
2
H), 3010 (br) (OH), 1154 (m) (N-N), 1540 (m) (C-
O)), 1480 (m) (COOs), 1600 (s) (COOas), 1620 (m) (TSC (C=N)), 1580 (m) ([(Sal-L-
tryp)] (C=N)), (1270) (m), (802) (m) (C=S), (454) (m) (V-S) and 976 (s) (V=O). 
Visible spectrum (DMSO), λmax./nm ( /M
-1
cm
-1
): 270 (sh) (10984), 288 (sh) (13874), 
330 (24837), 390 (sh) (18250), 620 (852). 
[VO(Sal-L-tryp)(acetylethTSC)].0.75C2H5OH 4. A 250 mL round bottom flask 
was thoroughly dried; then, 2-acetylthiozole-4,4'-dimethylthiosemicarbazone (0.12 g, 
0.51 mmol) and [VO(Sal-L-tryp)(H2O)] (0.20 g, 0.51 mmol) were placed in the 250 
mL round bottom flask. Absolute ethanol (40 mL) was added to the flask and the 
solution was refluxed with stirring under argon for two hours in an oil bath at 110
 ˚C.  
An orange-blue solution which was produced was then rotary evaporated to dryness.  
Diethyl ether was added to the product and the mixture was filtered under vacuum and 
dried. Yield = 0.18 g (57%).The purity was checked by elemental analysis. Calc. for  
C27.5H30.5N6O4.75 S2V: C, 51.92; H, 4.83; N, 13.21. Found: C, 52.49; H, 4.72; N, 
10.91. m/z (ESI) 600.25 (2.71%, [M+H]
+
), 513.57 (100.00%, [M -  C3H7NS + H]
+
), 
482.38 (37.11%, [M -  C7H5NO] + H]
+
), 336.06 (4.13%, [[M -  C17H15N2O] + H]
+
, 
636. 82 (2.75%, [M + 0.75 C2H5OH + H]
+
). FT IR ( /cm
-1
): 3229 (m) ( indolic NH), 
3310 (m) (-N
1
H), 2976 (m) (-N
2
H), 1149 (m) (N-N), 1545 (m) (C-O)), 1480 (m) 
(COOs), 1600 (s) (COOas), 1624 (m) (TSC (C=N)), 1580 (m) ([(Sal-L-tryp)] (C=N)), 
(1287) (m), (819) (m) (C=S), (455) (m) (V-S) and 982 (V=O). Visible spectrum 
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(DMSO), λmax./nm ( /M
-1
cm
-1
): 276 (21969), 352 (14227), 558 (80), 590 (sh) (70), 
756 (38). 
Oxidized [VO(Sal-L-tryp)(H2O)] (compound 1) in DMSO. [VO(Sal-L-
tryp)(H2O)] 1 (0.1 g, 0.26 mmol) and dimethylsulfoxide (10 mL) was placed in an 
evaporating dish and the resulting solution was left to evaporate for 32 days. Yield = 
0.09 g. m/z (ESI) (+ve mode) 468.60 (1.67, [M + H]
+
), 242.41 (100.00, [M - OH - 
DMSO - C8H7N + H]
+
), 451.05 (48.25, [M - OH + H]
+
), 763.68 (30.06, [[V2O3(Sal-L-
tryp)2] + H]
+
), 776.77 (49.36, [[V2O3(Sal-L-tryp)2(H2O)] + H]
+
) and 918.28 (3.13, 
[[V2O3(Sal-L-tryp)2(DMSO)2] + H]
+
). FT IR ( /cm
-1
): 3185 (m) ( indolic NH), 3194 
(br)(OH), 1551 (m) (C-O)), 1497 (m) (COOs), 1618 (s) (COOas), 1667 (m) (TSC 
(C=N)), 1581 (m) ([(Sal-L-tryp)] (C=N)), 1164 (m), 1213 (m) (S=O), 949 (s) (V=O). 
H (400 MHz; DMSO-d6); 2.52 (d) (3H) (H (a)), 2.52 (d) (3H) ((H (b)), 10.89 (s) (1H) 
(H (c)), 7.06 (S) (1H) (H (d)), 7.22 (m) (1H) (H (e)), 7.22 (m) (1H) (H (f)), 7.52 (d) 
(1H) (H (g)), 8.06 (d) (2H) (H (h)), 3.36 (s) (1H) (H (i)), 3.00 (s) (2H) (H (j)), 7.22 
(m) (1H) (H (k)), 7.22 (m) (1H) (H (l)), 7.22 (m) (1H) (H (m)), 7.22 (m) (1H) (H (n)), 
9.93 (s) (1H) (H (o)) and 7.06 (s) (1H) (H (p)). 
Oxidized [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O (compound 3) in 
DMSO. [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O 3 (0.1 g, 0.16 mmol)  and 
dimethylsulfoxide (10 mL) was placed in an evaporating dish and the resulting 
solution was left to evaporate for 32 days. Yield = 0.09 g. m/z (ESI) (+ve mode) 
470.01 (0.50, [M + H]
+
), 252.26 (100.00, [N-Ethhymethohcarbthio + H]
+
), 451.96 
(2.97, [M - OH + H]
+
), 702.75 (2.15, [M - OH + N-Ethhymethohcarbthio + H]
+
), 
763.22 (0.74, [[V2O3(Sal-L-tryp)2 + H]
+
), 775.40 (1.08, [[V2O3(Sal-L-tryp)2( H2O)] + 
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H]
+
) and 916.44 (0.75, [[V2O3(Sal-L-tryp)2( DMSO)2] + H]
+
). FT IR ( /cm
-1
): 3193 
(br)(OH), 1666 (m) (C=N), 1600 (C=O), 1550 (m) (C-O)), 1133 (m), 1157 (m) (S O), 
946 (s) (V=O). H (400 MHz; DMSO-d6); 2.52 (d) (3H) (H (a)), 2.52 (d) (3H) ((H 
(b)), 10.43 (s) (1H) (H (c)), 6.96 (s) (1H) (H (d)), 7.22 (m) (1H) (H (e)), 7.22 (m) 
(1H) (H (f)), 7.42 (d) (1H) (H (g)), 8.00 (d) (2H) (H (h)), 3.34 (s) (1H) (H (i)), 3.00 
(s) (2H) (H (j)), 7.22 (m) (1H) (H (k)), 7.22 (m) (1H) (H (l)), 7.22 (m) (1H) (H (m)), 
7.22 (m) (1H) (H (n)), 9.95 (s) (1H) (H (o)) and 6.96 (s) (1H) (H (p)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
 
CHAPTER III 
RESULTS AND DISCUSSIONS 
Synthesis and Characterization of the Ligands 
  Two novel thiosemicarbazones (E)-N-ethyl-2-(4-hydroxy-3 
methoxybenzylidene)hydrazinecarbothioamide (N-Ethhymethohcarbthio) and (E)-N-
ethyl-2-(1-(thiazol-2-yl)ethylidene)hydrazinecarbothioamide (acetylethTSC) were 
synthesized as shown in Scheme 5.  
 
 
Scheme 5.  Synthesis of the thiosemicarbazones. 
9-Anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC) was synthesized as by 
Beckford et al.
128
 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid (the 
reduced Schiff base) was also prepared using a known procedure
141
 involving 
salicylaldehyde, amino acids, and NaBH4, but with L-tryptophan (Scheme 6).   
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NH
NH
O
HO
HO
OH
O
H
(i) KOH/H2O, EtOH
30 min., RT
10 min., pH 4.68
(ii) NaBH4, NaOH
H2N
HN
O
HO
 
 
Scheme 6.  Synthesis of 2-(2-hydroxybenzylamino)-3-(1H-indol-3-yl)propanoic acid. 
 
Elemental and Mass Spectroscopic Analyses 
 
Elemental analyses were carried out on N-Ethhymethohcarbthio, and the 
percentage values found for C, H, and N as an assessment of the purity are discussed in 
this chapter.  ESI MS spectroscopic data were acquired for the reduced Schiff base and 
K[(Sal-L-tryp)] (See Appendix, Figures A1 and A2) and the data is presented in Table 2.  
The ESI MS data for the reduced Schiff base and K[(Sal-L-tryp)] were acquired in 
the positive ion mode of the mass spectrometer. The ESI MS spectrum acquired for the 
reduced Schiff base (using NH4OH/NH4CH3CO2 at pH 9.65 as solvent) revealed a base 
peak at m/z = 311.08, corresponding to [M + H]
+
 ion. Four peaks assigned to the 
fragments [M - CHO3 + H]
+
, [2M + H]
+
, [3M + H]
+
 and [4M + H]
+
 were also observed at 
m/z = 242.42, m/z = 620.36, m/z = 930.39, and m/z = 1240.97, respectively. The ESI MS 
spectrum of K[(Sal-L-tryp)], acquired in methanol, revealed a base peak at m/z = 300.03, 
which is attributed to the [M - HO - K + H]
+ 
ion. The peak at m/z = 344.05 was assigned 
to the [M + H]
+
 ion while the fragments at m/z = 205.20, m/z = 242.62, m/z = 262.12 and 
m/z = 281.14 were assigned to [M - C7H6O - K + H]
+
, [M - COO - OH - K + H]
+
, [M - 
COO - K + H]
+ 
and [M - OH - O - K + H]
+
, respectively. 
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Table 2 
  
 Mass spectroscopic data of the Reduced Schiff base (2-(2-hydroxybenzylamino)-3-(1H-
indol-3-yl)propanoic acid) and K[(Sal-L-tryp)]. 
 
 
Species 
 
Exact  
Mass/gmol
-1 
 
 
Species 
 
m/z 
 
Relative 
Intensity 
 
Reduced Schiff 
Base
 # 
 
 
 
 
K[(Sal-L-tryp)]
 #
 
 
310.13 
 
 
 
 
 
346.07 
 
 [M+ H]
+
 
 [M - CHO3 + H]
+
 
 [2M + H]
+
 
 [3M + H]
+
 
 [4M + H]
+ 
 
 [M + H]
+
 
 [M - OH - K + H]
+ 
 [M - OH - O - K + H]
+
 
 [M - COO - K + H]
+
 
 [M - COO - OH - K + H]
+
 
 [M - C7H6O - K + H]
+
 
 
311.08 
242.42 
620.36 
930.39 
1240.92 
 
344.05 
300.03 
205.20 
242.62 
262.12 
281.14 
 
100.00 
13.04 
12.77 
5.02 
3.92 
 
39.65 
100.00 
50.43 
64.65 
1.51 
46.08 
 
# - positive mode 
 
X-ray Crystallographic Studies on AcetylethTSC 
 
A single crystal of acetylethTSC was grown by slow evaporation of a solution 
containing methanol as solvent.  The molecular structure with the atomic numbering 
scheme of acetylethTSC is shown in Figure 28 while Table 3 shows the crystal data and 
structure refinement (see Appendix, Figures AJJ-AMM for selected bond lengths and 
angles).  
The molecule was observed to be nearly planar with its 14 non-hydrogen atoms 
having a mean deviation of 0.029 Å from their mean plane. The largest deviation is 
0.0719(4) Å for S2 as a result of a very slight tilt of the thiazole ring from the rest of the 
molecule as given by the S2-C3-C2-N1 torsion angle, 3.3(2)º. The near-planarity of the 
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molecule is likely due to the N3-H...N1 intramolecular interaction with N...N distance 
2.588(2) Å, H...N distance 2.20(2) Å, and a rather small N-H...N angle for a hydrogen 
 
Figure 28.  An ORTEP diagram of acetylethTSC (identification code = Venkat35). 
 
Table 3   
 
Crystal data and structure refinement for acetylethTSC (identification code = Venkat35).  
 
 
Identification code 
 
 
Venkat35  
  
Empirical formula C8H12N4S2  
 
Formula weight 228.34  
 
Temperature  90.0(5) K  
 
Wavelength  1.54178 Å  
 
Crystal system, space group Monoclinic,  C2/c    
 
Unit cell dimensions a = 10.4549(10) Å,   = 90º  
b = 10.8970(10) Å,   = 91.544(5)º 
c = 18.7694(15) Å,   = 90º 
Volume   2137.6(3) Å
3 
 
Z, Calculated density  8,  1.419 Mg/m
3
  
 
Absorption coefficient 4.251 mm
-1
  
 
F(000) 960  
 
Crystal size 0.18 x 0.17 x 0.09 mm  
 
Theta range for data collection 5.8 to 68.1º 
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Table 3 (continued). 
 
Identification code 
 
 
Venkat35  
  
Limiting indices -12<=h<=12, -12<=k<=13, -22<=l<=22  
 
Reflections collected / unique 8017 / 1901 [Rint = 0.026]  
 
Completeness to theta = 66.6º  99.1%  
 
Absorption correction Semi-empirical from equivalents  
 
Max. and min. transmission 0.701 and 0.515  
 
Refinement method  Full-matrix least-squares on F
2
  
 
Data / restraints / parameters 1901 / 0 / 136  
 
Goodness-of-fit on F
2
 1.065  
 
Final R indices [I>2 (I)] R1 = 0.0276, wR2 = 0.0691  
 
R indices (all data) R1 = 0.0312, wR2 = 0.0715  
 
Extinction coefficient 0.00011(3)  
 
Largest diff. peak and hole 0.257 and -0.262 e Å
 -3
  
 
 
bond, 110(2)º. The N1=C2 formal double bond has distance 1.284(2) Å, the N1-N2  
distance is 1.3691(18) Å, and the thione distance C1=S1 is 1.6814(16) Å. It is known that 
the thiosemicarbazone group can present a thione-thiol tautomerism.
128
 The C(1)-S(1) 
distance (1.6814 Å) is similar to that found in a methyl analogue of 2-acetyl-2-thiazoline 
thiosemicarbazone which is in the thione form as a solid,
145
 which indicates that 
acetylethTSC is in that form. The N2-H group donates an intermolecular hydrogen bond 
to thione S1, forming centrosymmetric hydrogen-bonded dimers with N...S distance 
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3.4651(15) Å. Thiazole N atom N4 is not involved in hydrogen bonding as shown in 
Figure 29. 
 
Figure 29.  Hydrogen bonding in acetylethTSC (identification code = Venkat35). 
 
FT IR Spectroscopy 
 Thiosemicarbazones are known to exhibit characteristic bands in specific 
energy regions corresponding to various functional groups.
128,146
 FT IR spectra were 
acquired for each ligand (see Appendix, Figures A3-A7) and significant FT IR 
spectral bands of the free ligands are shown in Table 4. FT IR
 
spectral data obtained 
for the reduced Schiff base and K[(Sal-L-tryp)] are also presented and used to confirm 
the existence of various spectral bands observed in the FT IR spectra of the free 
ligands.   
 The stretching frequencies of the N-H), (C N), and (C S) functional 
groups are very useful when determining the mode of coordination of the 
thiosemicarbazone ligands.
147
 The corresponding spectral bands occur in the regions 
3100 - 3500 cm-1, 1580 - 1630 cm-1, 1000 - 1200 cm-1 and 820 - 900 cm-1, 
respectively.
147
 Thiosemicarbazones have been shown to exhibit thione-thiol
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Table 4   
FT IR data for the ligands. 
 
Compound 
Indolic 
(NH) 
/cm-1 
–N1H2  
(NH) 
/cm-1 
N2H  
(NH) 
/cm-1 
  (N-N) 
     /cm-1 
  (C-O) 
/cm-1 
s (COO) 
/cm-1 
as (COO) 
/cm-1 
TSC 
(C=N) 
/cm-1 
Sal-L-
tryp 
(C=N) 
/cm-1 
(C=S) 
/cm-1 
(V-S) 
/cm-1 
(OH) 
/cm-1 
MeATSC - 3399 (m) 3201 (w) 
1075 
(m) 
- - - 1621 (m) - 
1255 (m), 841 
(m) 
- - 
N-Ethhymethohcarbthio - 3304 (m) 3300 (w) 1155 (m) - - - 1606 (m) - 
1267 (m), 831 
(m) 
- 3130 (br) 
AcetylethTSC - 3164 (m) 3054 (w) 1059 (m) - - - 1543 (m) - 
1296 (m), 813 
(m) 
- - 
K[(Sal-L-tryp)] 3407 (m) - - - 1194 (m) 1521 (m) 1604 (m) - 
1570 
(m) 
- - 3169 (br) 
Reduced Schiff base 
ligand 
3392 (m) - - - 1208 (m) 1494 (m) 1592 (m) - - - - 3055 (br) 
  
 
 
 
 
 
 
 
 
5
2
 
53 
  
 
 
tautomerism due to the presence of a thioamide -NH-C=S functionality (Figure 30).
148
 
Recently, it was reported that thiosemicarbazones can coordinate to metal centers 
 
 
Figure 30.  Tautomerism in thiosemicarbazones.
128
 
either as a neutral (thione) or as a mono-anionic (thiolate) ligand.
128
 The question of 
thione-thiol tautometism in the ligands were ruled out due to the absence of a 
characteristic  ((S-H) spectral band (in the region 2600 to 2500 cm
-1
) in the 
respective FT IR spectra.
147,149-151
 The FT IR spectra of the ligands in our case also 
exhibited two stretching frequencies in the (N-H) region, confirming that the ligands 
are coordinated as the thione form.
128,148,152-154
 
  When evaluating the nature of the bonding in thiosemicarbazone complexes, 
the (N-H) stretching frequency is known to play a very important role.
155
 The bands 
assigned to (N-H) can be split into two regions: (i) 3450 to 3210 cm
-1
 due to the -
N
1
H2 group, (ii) 3180 to 3150 cm
-1
 due to the -N
2
H group.
146
 The (N-H) stretching 
frequency of the -N
1
H2 group was observed at 3399 cm
-1
, 3304 cm
-1
,
 
and 3164 cm
-1 
for MeATSC, N-Ethhymethohcarbthio, and acetylethTSC, respectively. The (N-H) 
stretching frequency of the -N
2
H group was observed 3201 cm
-1
, 3300 cm
-1
, 3054 cm
-
1
 and 2831 cm
-1
 for MeATSC, N-Ethhymethohcarbthio, acetylethTSC, and the 
reduced Schiff base, respectively.  
  Stretching frequencies observed in the regions 1620 to 1605 cm
-1
 are 
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commonly assigned to the (C=N) moiety of the thiosemicarbazone 
ligands.
148,152,153,156
 Spectral bands corresponding to (C=N) moiety were observed at 
1621 cm
-1
, 1606 cm
-1
, and 1543 cm
-1
 for MeATSC, N-Ethhymethohcarbthio, and 
acetylethTSC, respectively.
128
 A similar stretching frequency was also observed at 
1570 cm
-1
 in the FT IR spectrum of K[(Sal-L-tryp)], corresponding to the azomethine 
group of the Sal-L-tryp moiety.
142
 The absence of a similar (C=N) stretching 
frequency in the FT IR spectra of the reduced Schiff base suggested that the ligand 
was successfully formed and confirmed the accuracy of the assignment.  
 Spectra bands of medium intensity observed in the regions 841-816 cm
-1
 and 
1255-1295 cm
-1
 for each thiosemicarbazone ligand was assigned to the stretching 
frequency (C S) moiety.
152,157,158
 Stretching frequencies assigned to the (C S) moiety 
were observed at 841 cm
-1
, 831 cm
-1
 and 813 cm
-1
, and 1255 cm
-1
, 1267 cm
-1
 and 1296 
cm
-1
 for MeATSC, N-Ethhymethohcarbthio and the acetylethTSC, respectively.  
NMR Spectral Studies 
 NMR spectral data were acquired for N-Ethhymethohcarbthio ligand, 
acetylethTSC, the reduced Schiff base, and K[(Sal-L-tryp)]. Based on the solubility of 
our ligands, N-Ethhymethohcarbthio, acetylethTSC and K[(Sal-L-tryp)] were dissolved in 
DMSO-d6 whereas the reduced Schiff base was dissolved in D2O/NaOD at pH 9. Figure 
31 shows the lettering system used for the assignments of protons and carbons in the 
experimental section for the reduced Schiff base and K[(Sal-L-tryp)] (see Appendix, 
Figures A8 to A11).  
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Figure 31.  Assignments used for the 
1
H and 
13
C NMR data acquired for the reduced 
Schiff base and K[(Sal-L-tryp)] in DMSO-d6. 
 
N-Ethhymethohcarbthio and AcetylethTSC 
 
  The 
1
H NMR spectra of N-Ethhymethohcarbthio and acetylethTSC are shown 
in Figures 32 and 33. The basic component of thiosemicarbazone ligand system is 
generally represented by the moiety: -C
2
=N
3
-N
2
H-C
1
.
146
 In order to demonstrate the 
usefulness of NMR in the characterization of metal-ligand bonding, the NMR (
1
H 
and
13
C) data of the rings at C
2
 carbon of N-Ethhymethohcarbthio and acetylethTSC is 
briefly delineated.
146
 
  In the 1H NMR spectra of N-Ethhymethohcarbthio and acetylethTSC, a singlet 
at 11.42 ppm and 10.61 ppm, similar to the previously reported data of MeATSC and 
ATSC thiosemicarbazone ligands, was also present.
128,147,159
 Based on spectroscopic 
data available in the literature, these signals are inferred to be due to the N(2)-H 
protons.
152,159,160
 The hydrazinic protons (N(2)-H) of “free” thiosemicarbazone 
ligands are known to appear as single broad peaks in a fairly wide range (  = 8.7 -15 
ppm) depending on the nature of the substituents at C2 carbon atom.
146,161-164
 This 
signal is therefore used as a diagnostic test for the identification of isomers.
128
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Figure 32.  
1
H NMR spectra of N-Ethhymethohcarbthio in DMSO-d6. 
 
5
6
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Figure 33.  
1
H NMR spectra of acetylethTSC in DMSO-d6.  
5
7
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 According to Afrasiabi,
165
 a  resonance signal in the range  = 13-15 ppm, 
suggests that the ligand is in the E form. A resonance signal in the range  = 9-12 
ppm, however, suggests that the ligand is in the Z form.  Based on this analysis, the 
N-Ethhymethohcarbthio and acetylethTSC ligands both existed as the respective Z 
isomers. The lack of a resonance signal at ca.  = 4.0 ppm attributable to a -SH proton 
resonance confirmed that both ligands existed in the thione form when in solution 
(even a solvent  as polar as DMSO).
128
 An X-ray crystallographic study on  
acetylethTSC also confirmed the existence of the thione moiety 
.   The azomethine (-C
2
H) protons of free thiosemicarbazone ligands have been 
reported to resonate in the range  = 6.6 to 7.9 ppm.
146,147
 The singlet observed at  = 
7.57 ppm in the NMR spectrum of the N-Ethhymethohcarbthio ligand was therefore 
assigned to the azomethine moiety. Although a similar peak was absent in the 
1
H 
NMR spectrum of acetylethTSC, a singlet observed at 2.42 ppm was assigned to the 
methyl group present at C
2
 atom.  
 The resonance signals observed at   = 8.43 ppm and 8.34 ppm were assigned 
to proton of the N
1
H(R) group (where R = ethyl group) in N-Ethhymethohcarbthio 
and acetylethTSC, respectively.
128
 Quintets assigned to methylene protons were 
observed at  = 3.60 ppm and  = 3.61 ppm for N-Ethhymethohcarbthio and 
acetylethTSC, respectively. Adjacent methyl protons were observed as triplets at  = 
1.15 ppm and  = 1.14 ppm for N-Ethhymethohcarbthio and acetylethTSC, 
respectively. In the
13
C NMR spectra, the corresponding resonance signals for the 
methylene and the methyl carbons were also observed at  = 38.28 ppm and  = 14.60 
ppm, respectively. 
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 In the 
1
H and 
13
C spectra of N-Ethhymethohcarbthio, a resonance signal 
observed at  = 3.46 ppm was assigned to the methoxy protons while the 
corresponding carbon signal was observed at  = 58.85 ppm. The resonance signals 
observed at  = 11.41 ppm and in the region  = 6.76-7.57 ppm were assigned to the 
phenolic proton (PhOH), and the aromatic protons of the N Ethhymethohcarbthio 
ligand, respectively.
147
 
  The resonance signals assigned to the C
1
 and C
2
 carbon atoms of free 
thiosemicarbazones are known to appear in the ranges,  = 177.40 to 178.86 ppm and 
 = 132.56 to 163.43 ppm, respectively.
146
 In the 
13
C NMR spectrum of N-
Ethhymethohcarbthio, the resonance signals observed at  = 176.50 ppm and  = 
177.54 ppm were therefore assigned to the C
1
 and C
2
 carbon atoms, respectively. All 
other aromatic signals were observed in the range  = 112 to  = 146 ppm.
128
  
Electrochemical Studies 
The electrochemical analysis of thiosemicarbazone ligands is very sparse in 
literature. In this section we attempted to analyze the electrochemical properties of our 
“free” ligands. Figures 34 and 35 (See Appendix, Figures A13 and A14 for the square 
wave voltammograms for the ligands) shows the respective cyclic voltammograms for 
each ligand. Table 5 shows the data obtained from electrochemical studies of all ligands. 
The assignment of redox peaks were done using the cyclic voltammograms shown in 
Figures 34 and 35. Square wave voltammograms within the potential window of 0 to 
+1.0 V versus Ag/Ag+ (See Appendix, Figures A13 and A14) were used in order to  
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Figure 34. A cyclic voltammogram of a 1.0 mM solution of K[(Sal-L-tryp)] in DMSO. 
Electrodes: platinum working electrode, platinum auxiliary electrode and Ag/Ag
+
 (0.01 
M AgNO3 and 0.10 M TBAP in acetonitrile) reference electrode. Supporting electrolyte = 
0.1 M TBAP. Scan rate = 100 mV s
-1
. 
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Figure 35.  Cyclic voltammograms of 1.0 mM solutions of thiosemicarbazone ligands in 
DMSO. Electrodes: platinum working electrode, platinum auxiliary electrode and 
Ag/Ag
+
 (0.01 M AgNO3 and 0.10 M TBAP in acetonitrile) reference electrode. 
Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s
-1
. 
 
confirm the assignments made based on cyclic voltammetry. Previously reported 
electrochemical studies have shown that L-tryptophan produces an irreversible anodic 
peak in the region +0.8 V to +0.9 V versus Ag/Ag
+
 at a scan rate of 100 mV s
-1
.
166,167
 
pH studies involving the electrochemical oxidation of L-tryptophan have proven that 
L-tryptophan is oxidized via a two electron/two proton process occurring at the amine 
group (of the indole moiety) and the methyl group (present in the side chain).
168
 A 
similar irreversible anodic peak corresponding to the oxidation of L-tryptophan  
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Table 5 
 
 Electrochemical data of 1.0 mM solutions of ligands.  
 
 
Species 
 
 
E/V 
 
Assignment 
 
[K(Sal-L-tryp)] 
 
Epa  =  +0.75 
Epa   =  +0.16 
E1/2   =  -0.21 
Epc   =  -0.97 
Epc   =  -1.50 
 
 
L-tryp
0/+
 
PhO
-/. 
PhO
-/. 
- 
L-tryp
+/0
 
MeATSC Epa  =  +0.84 
Epa   =  +0.75 
Epa   =  +0.60 
Epa   =  -0.17 
E1/2   =  -1.63 
Epc   =  -0.14 
Epc   =  -0.49 
Epc   =  -0.93 
 
R2C=S
0/+.
 
 
Oxidation of anthracene moiety 
 [R2C=S]
0/+.
 → [R2C-S-S-CR2]
2+
 + 2e
- 
formation of cation radical 
HC=N/CH2-NH  
reduction of cation radical 
reduction of disulfide cation 
C=S → C=SH 
 
N-
Ethhymethohcarbthio 
Epa  =  +0.80 
Epa   =  +0.51 
Epa   =  +0.37 
Epa   =  -0.17 
Epa   =  -1.11 
E1/2  =  -1.60 
Epc   =  -0.36 
Epc   =  -0.52 
Epc   =  -1.08 
 
R2C=S
0/+.
 
 
[R2C=S]
0/+.
 → [R2C-S-S-CR2]
2+
 + 2e
- 
Oxidation of  phenolate in vanillin 
moiety 
formation of cation radical 
formation of cation radical 
HC=N/CH2-NH  
reduction of cation radical 
reduction of disulfide cation 
C=S → C=SH 
 
AcetylethTSC Epa  =  +0.85 
Epa   =  +0.75 
Epa   =  +0.48 
Epa   =  -0.17 
Epa   =  -1.04 
Epa   =  -1.38 
Epa   =  -1.61 
Epc   =  -0.25 
Epc   =  -0.53 
Epc   =  -0.86 
Epc   =  -1.07 
R2C=S
0/+.
 
 
- 
 [R2C=S]
0/+.
 → [R2C-S-S-CR2]
2+
 + 2e
- 
formation of cation radical 
formation of cation radical 
- 
HC=N/CH2-NH  
reduction of cation radical 
reduction of disulfide cation 
- 
C=S → C=SH 
Note. Electrodes: platinum working electrode, platinum auxiliary electrode and Ag/Ag+ (0.01 M AgNO3 and 0.10 M TBAP in 
acetonitrile) reference electrode. Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s-1. 
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was also observed at +0.75 V in the CV of K[(Sal-L-tryp)] (Figure 34). The 
assignment of this peak was also confirmed by the appearance of a similar anodic 
redox peak at +0.60 V in the SQW voltammogram of K[(Sal-L-tryp)] (see Appendix, 
A13). The existence of an irreversible cathodic peak, corresponding to catalytic 
hydrogen reduction, have also been reported during electrochemical studies of L-
tryptophan.
169-171
 In the CV of K[(Sal-L-tryp)], the irreversible cathodic peak 
observed at -1.5 V was assigned to catalytic hydrogen reduction.  
 Based on similar work reported by Thomas et al.,
172
 an irreversible anodic redox 
peak at +0.16 V in the cyclic voltammogram of K[(Sal-L-tryp)] was also assumed to be 
due to the phenolate moieties to form into a phenoxyl radical. This assignment was also 
confirmed by the appearance of an anodic redox peak at +0.12 V in the square wave 
voltammogram of K[(Sal-L-tryp)]. The redox potential of the one-electron transfer 
assigned to the oxidation of the phenolate moiety was also observed to vary depending on 
the electrostatic environment surrounding the redox active phenolate group.
172
 A 
reversible redox wave at E1/2 = -0.21 V, attributed to the phenoxyl/phenolate redox couple 
of the non-coordinated, electron-rich phenolate moiety, was also observed in the cyclic 
voltammogram of K[(Sal-L-tryp)].
172
 
  Recently, electrochemical studies of thiosemicarbazones has shown the 
existence of an  irreversible cathodic redox peak in the region, -1.26 V to -1.67 V, 
corresponding to the reduction of the imine moiety of the thiosemicarbazone 
functional group.
50,159,173
 An increase in the electron withdrawing character of 
substituents present in a compound is known to have a significant effect on the 
stability of the respective compound.
174
  The presence of electron donating substituent 
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increases the electron density at the reduction centers, making the respective 
compound more susceptible to oxidation and therefore less stable.
174
 The reversible 
nature of the redox peaks (attributed to the reduction of the imine moiety) observed 
for our thiosemicarbazone ligands is therefore accounted for by the presence of non 
electroactive electron withdrawing groups on the iminic carbon of the respective 
thiosemicarbazone ligands.
174
 The cyclic voltammogram of each ligand exhibited a 
reversible redox waves corresponding to the reduction of the imine moiety.
50,159,173
 
This reversible redox wave was observed at -1.63 V, -1.60 V and -1.61 V for 
MeATSC, N-Ethhymethohcarbthio, and acetylethTSC ligand, respectively.  
 Thiocarbonyl compounds, including thioureas, thiocaronates, and mono- and 
dithiocarbamates, are known to produce stable dimeric dications containing disulphide 
linkages upon chemical oxidation.
175,176
 An outline of the suggested oxidative electron-
transfer mechanism of our thiosemicarbazone ligands is shown in Scheme 7. Recently, 
the cyclic voltammograms of thioureas were shown to exhibit two irreversible anodic 
redox  peaks, as well as an irreversible cathodic redox peak resulting from the reduction 
of an oxidation product.
175,176
  
 The cyclic voltammogram of each ligand exhibited two similar irreversible anodic 
redox peaks and a corresponding irreversible anodic redox peak. These peaks were 
suggested to be due to the formation of cationic species as shown in Scheme 7. 
Irreversible anodic redox peaks at were observed at +0.84 V and +0.60 V for MeATSC, 
+0.80 V and +0.51 V for N-Ethhymethohcarbthio and at +0.85 V and +0.48 V for 
acetylethTSC. The anodic redox peaks observed at +0.60 V, +0.51 V and +0.48 V were 
suggested to result from the oxidation of the respective thiosemicarbazone ligands to a 
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Scheme 7.  Electrochemical oxidation of the thione group of a thiosemicarbazone to form 
a dimeric cation. 
 
highly reactive radical cation followed by the formation of a dimeric species 
containing a disulphide bond.
176
 According to Scheme 7, dimerization occurs either 
by direct coupling of two radical cations or by the addition of a radical cation to a 
neutral thiosemicarbazone ligand.
176
 The irreversible anodic redox peaks observed at 
+0.84 V, +0.80 V and +0.85 V were therefore assigned to the one-electron oxidation 
of the resultant dimeric radical cation.
176
  
  The reduction of the thione functional group of a thiosemicarbazone moiety, 
have previously been reported to produce an irreversible cathodic peak at -1.06 V.
177-
179
 Previously reported electrochemical studies on thiosemicarbazone ligands have 
also shown the existence of an irreversible cathodic peak at -1.06 V.
177-179
 Similar 
irreversible cathodic peaks (assigned to the reduction of the thione group) were also 
observed at -0.93 V, -1.08 V and -1.07 V, for MeATSC, N-Ethhymethohcarbthio, and 
acetylethTSC, respectively. 
 According to Refaey et al.,
174
 thiosemicarbazones are capable of participating in a 
series of  electrochemical oxidation reactions which eventually leads to the generation of 
radical cations.
174
 Electrochemical oxidative reactions (Scheme 8) were also evident in 
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our case as illustrated by the presence of at least one irreversible anodic redox peak in the 
cyclic voltammogram of each thiosemicarbazone ligand. The irreversible anodic redox 
peaks corresponding to the generation of radical cations were observed at -0.17 V for 
MeATSC, at -0.17 V and at -1.11 V for N-Ethhymethohcarbthio, and at -0.17 V and -1.04 
V for acetylethTSC. The previously formed radical cations later react with residual water 
present in the medium to form adducts, which undergoes the abstraction of a second 
proton to form thiadiazoles.
174
 The appearance of additional irreversible cathodic redox 
peaks are reported to be attributed to subsequent reduction of the previously formed 
radical cations.
174
 Irreversible cathodic redox peaks, observed at -0.14 V, -0.36 V and – 
0.25 V, were therefore assigned to the reduction of cation radicals for MeATSC, N-
Ethhymethohcarbthio, and acetylethTSC, respectively. 
 According to Li et al.,
180
 oxidation of vanilllin is also known to proceed through 
the production of relatively stable carbocation species. The oxidation of vanillin was 
shown to produce a quasi-reversible redox wave with the oxidative and reductive peak 
occurring at +0.19 V and +0.14 V, respectively. We are also proposing a similar 
oxidative reaction for our N-Ethhymethohcarbthio thiosemicarbazone ligand.  In our case, 
however, an irreversible anodic redox peak corresponding to the oxidation of the vanillin 
moiety of the N-Ethhymethohcarbthio ligand was observed at +0.37 V. All other ligand 
based peaks that were not mentioned in this discussion is assumed to be due to the 
formation of cation radical species. 
  The cyclic voltammogram of anthracene is known to exhibit a reversible 
redox wave in the region +0.84 V to +0.90 V.
181,182
 An irreversible anodic redox peak at 
+0.75 V was observed in the cyclic voltammogram of MeATSC. This irreversible anodic 
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Scheme 8.  Proposed electrochemical oxidation of the thione group.
174
 
 
redox peak was assigned to the oxidation of the anthracene moiety present in the 
MeATSC ligand. This assignment was also confirmed by the appearance of an anodic 
redox peak at +0.82 V in the square wave voltammogram of the MeATSC ligand.  
 
 
 
68 
  
 
 
Synthesis and Characterization of the Complexes 
Elemental and Mass Spectroscopic Analyses 
 
  Elemental analyses were carried out on compounds 1-4. Table 6 shows the 
respective percentage values found for C, H, and N as an assessment of the purity for 
the respective compounds.  The percentage of N found in compound 4 was 10.91% 
versus the calculated value of 13.21%.  This discrepancy is suggested to be due to 
experimental errors and loss of ethanol as solvate during the elemental analysis. ESI 
MS analysis of compound 4,  as discussed below proves the existence of the species,  
Table 6  
Elemental analysis data for compounds 1-4. 
 
Compound 
 
  
Calculated 
 
Found 
 
1 
 
C 
 
55.25 
 
55.16 
H 4.12 4.31 
N 7.16 6.87 
    
 
2 
C 62.03 62.62 
H 5.21 5.25 
N 9.52 9.33 
    
 
3 
C 53..33 53.18 
H 4.64 5.21 
N 11.11 11.09 
    
 
4 
C 51.92 52.49 
H 4.83 4.72 
N 13.21 10.91 
 
 
[VO(Sal-L-tryp)(acetylethTSC)] and [VO(Sal-L-tryp)(acetylethTSC)]0.75C2H5OH. 
ESI MS spectral data were acquired for compounds 2-4, [Zn(Sal-L-
tryp)(H2O)].0.25H2O and the products obtained from oxidised DMSO solutions of 
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compounds 1 and 3 (see Appendix, Figures A15-A22). Table 7 shows the ESI MS 
data acquired for the respective complexes while Schemes 9-11 shows the proposed 
species formed during ESI MS acquisition compounds 2-4. 
  Compounds 2-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O. The ESI MS spectra of 
compounds 2-4 were acquired in methanol. Each spectra exhibited base peaks 
corresponding to the respective molecular ions. These peaks were observed at m/z = 
666.17, m/z = 624.87, and m/z = 513.57 for compounds 2, 3, and 4, respectively. Base 
peaks obtained for compounds 2 and 4 were observed in the positive ion mode of the 
mass spectrometer. The base peak for compound 3, however, was observed in the 
negative ion mode of the mass spectrometer due to the deprotonation of the phenol 
moiety of the N-Ethhymethohcarbthio ligand. All other fragments observed for 
compound 2-4 are assigned as shown in Table 7. 
 The ESI MS spectrum of [Zn(Sal-L-tryp)(H2O)].0.25H2O was acquired in the 
positive mode of the spectrometer and methanol was used as the solvent.  The peak at 
m/z = 395.11 was assigned to the [M + H]
+
 ion. X-ray crystallographic studies of 
similar [N-salicylidene-L-aminoacidato)Zn(II)] complexes have proven that these 
complexes are capable of forming binary and polymeric species.
143
 The base peak, 
attributed to the formation of a trinuclear species, was therefore observed at m/z = 
1152.92 in the ESI MS spectrum of [Zn(Sal-L-tryp)(H2O)].0.25H2O. All other peaks 
(corresponding to the formation of various polymeric species) were assigned as 
shown in Table 7. 
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Table 7   
 
Mass spectroscopic data of compounds. 
 
(A)     Compounds 1-4, and [Zn(Sal-L-tryp)(H2O)].0.25H2O. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 # - positive mode             
 † -negative mode 
 
Species 
 
Exact 
 Mass/gmol
-1
 
Species m/z 
Relative 
Intensity 
[VO(Sal-L-tryp)(MeATSC)]
 #
 666.14 
  
[M + H]
+
 
 
666.17 
 
100.00 
 [M -  C2H5N2S + H]
+
 577.08 33.10 
 [M - C17H17N3 + H]
+ 
405.14 31.86 
 [MeATSC+ H]
+ 
 
292.14 
 
54.60 
 
[VO(Sal-L-tryp)(N-Ethhymethohcarbthio)]
 † 
 626.13 
 [M - H]
-
 624.87 100.00 
 [M - C11H10N2O - H]
-
 431.90 64.75 
 [M - C11H15N3O2S - H]
-
 407.85 20.99 
 [[C11H15N3O2S – C8H7N] - H]
-
 287.88 12.70 
 [N-Ethhymethohcarbthio- H]
- 
 
252.00 
 
25.74 
 
[VO(Sal-L-tryp)(acetylethTSC)]
 #
 601.09 
[M + H]
+
 600.25 2.71 
 [M - C3H7NS + H]
+ 
513.57 100.00 
 [M - C7H5NO + H]
+
 482.38 37.11 
 [M - C17H15N2O + H]
+ 
 
336.06 
 
4.13 
 
[VO(Sal-L-tryp)(acetylethTSC)].0.75 C2H5OH
#
 635.62 
 [[VO(Sal-L-
tryp)(acetylethTSC)].0.75 C2H5OH 
+ H]
+ 
 
636. 82 2.75 
[Zn(Sal-L-tryp)(H2O)].0.25 H2O 
#
 392.54 
 
[M+ H]
+
 395.11 13.93 
7
0
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Table 7 (continued).     
 
   (B)  Oxidized products isolated from compounds 1 and 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 a - product obtained from compound 1 
 b - product obtained from compound 3 
 # - positive mode 
 
 
Species 
Exact 
Mass/gmol
-1
 
Species m/z 
Relative 
Intensity 
 
[VO(Sal-L-tryp)(DMSO)(OH)]
 a, #
 
 
468.06 
 
[M + H]
+
 
 
468.60 
 
1.67 
[M - OH - DMSO - C8H7N + H]
+
 242.41 100.00 
[M - OH + H]
+ 
451.05 48.25 
 [[V2O3(Sal-L-tryp)2] + H]
+ 
763.68 30.06 
[[V2O3(Sal-L-tryp)2(H2O)] + H]
+
 776.77 49.36 
[[V2O3(Sal-L-tryp)2(DMSO)2] + H]
+ 
 
918.28 
 
3.13 
 
[VO(Sal-L-tryp)(DMSO)(OH)]
 b, #
 468.06 [M + H]
+
 470.01 0.50 
[N-Ethhymethohcarbthio + H]
+
 252.26 100.00 
[M - OH + H]
+ 
451.96 2.97 
[M - OH + N-Ethhymethohcarbthio + H]
+
 702.75 2.15 
[[V2O3(Sal-L-tryp)2 + H]
+ 
763.22 0.74 
[[V2O3(Sal-L-tryp)2( H2O)] + H]
+
 775.40 1.08 
[[V2O3(Sal-L-tryp)2( DMSO)2] + H]
+ 
 
916.44 
 
0.75 
 
7
1
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Scheme 9.  Proposed species found during ESI MS acquisition of compound 2. 
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Scheme 10.  Proposed species found during ESI MS acquisition of compound 3. 
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Scheme 11.  Proposed species found during ESI MS acquisition of compound 4. 
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  Oxidized products isolated from Compounds 1 and 3. Oxovanadium(IV) 
complexes containing N-salicylidene-L-aminoacidatos ligands are readily oxidized to 
form vanadium(V) compounds.
60
 Our data suggested that compounds 1-4 were readily 
oxidized to form vanadium(V) upon aerial oxidation in DMSO. In this study, 
however, we will focus on compounds 1 and 3. ESI MS spectra of the products 
obtained from the oxidized solutions of compounds 1 and 3 were acquired in both the 
positive and negative ion mode of the spectrometer (see Appendix, Figures A19 to 
A22). Assignments of spectral peaks (as shown in Table 7) were done using the 
spectra obtained in the positive ion mode of the sprectrometer.  
  As reported by Cavaco et al.,
60
 coordinated water molecules present in 
oxovanadium(IV) complexes, such as [VO(Sal-L-ala)(H2O)], are readily substituted 
by solvent molecules such as methanol. Upon substitution of solvent molecules, the 
vanadium(V) species formed readily dimerizes to form binuclear species.
60
 It is 
suggested that our compounds behaved similarly when oxidized. A proposed scheme 
showing the aerial oxidation of compounds 1 and 3 in DMSO are shown in Scheme 
12. 
 The ESI MS spectra of the products (obtained from oxidized solutions of 
compounds 1 and 3) both exhibited spectral peaks attributed to the [VO(Sal-L- 
tryp)(DMSO)(OH) + H]+ ion, when analyzed in the positive mode of the spectrometer. 
Spectral peaks observed at m/z = 468.60 and m/z = 470.01 were assigned to the [VO(Sal-
L-tryp)(DMSO)(OH) + H]+ ion for products obtained from oxidized solutions of 
compounds 1 and compound 3, respectively (see Table 7). The ESI MS spectra acquired 
for the oxidized products isolated from compounds 1 and 3 also exhibited peaks 
76 
  
 
 
 
 
Scheme 12.  Proposed mechanism for the formation of the oxidized compounds in 
DMSO. 
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attributed to the presence of the vanadium(IV) species, [VO(Sal-L-tryp)(OH)]
-
, at m/z = 
388.94 and m/z = 386.78, respectively. The spectrum acquired for the oxidised product 
obtained from compound 3 in DMSO also exhibited a base peak at m/z = 252.26, which 
was attributed to the “free” N-Ethhymethohcarbthio ion.  This presence of this species 
also confirms the formation of [VO(Sal-L-tryp)(DMSO)(OH)] in the proposed 
mechanism for the formation of the oxidized compounds in DMSO (Scheme 12). 
As mentioned earlier, oxovanadium(IV) complexes are known to form 
vanadium(V) binuclear complexes upon oxidation.
60
 The ESI MS spectra acquired for 
both products obtained from oxidized solutions of compounds 1 and 3, both exhibited 
several peaks corresponding to the formation of mixed binuclear species in the positive 
ion mode of the spectrometer. Peaks assigned to the formation of the binuclear 
[V2O3(Sal-L-tryp)2(DMSO)2] species were observed at m/z = 918.28 and m/z = 916.44, 
for the oxidized products obtained from compound 1 and compound 3, respectively. 
The ESI MS spectrum of the product obtained from the oxidized solution of compound 3 
also exhibited a peak at m/z = 702.75. This peak is proposed to be due to the ion formed 
when the “free” N-Ethhymethohcarbthio ligand coordinates to the [VO(Sal-L-
tryp)(DMSO)(OH)] species via the phenolate moiety of the “free” N-
Ethhymethohcarbthio ligand (see Scheme 12). 
FT IR Spectroscopy 
Compounds 1-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O. FT IR spectra were 
acquired for compounds 1-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O (see Appendix, 
Figures A23-A27) and significant FT IR spectral bands are shown in Table 8 (A). A 
general decrease is observed in the (N-H) stretching frequency of the -N
1
H2 group 
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upon coordination of thiosemicarbazone ligands. Coordination of the respective 
“free” thiosemicarbazone ligands to the vanadium(IV) metal center results in a shift in 
the the (N-H) stretching frequencies from 3399 cm
-1 
to 3308 cm
-1
 for compound 2, 
3340 cm
-1
 to 3306 cm
-1
 for compound 3, and 3358 cm
-1
 to 3310 cm
-1
 for compound 4. 
A decrease was also observed in the (N-H) stretching frequencies of the -N
2
H group 
from 3201 cm
-1 
to 2976 cm
-1
 for compound 2, 3300 cm
-1
 to 2970 cm
-1
 for compound 
3, and 3169 cm
-1
 to 2976 cm
-1
 for compound 4. 
 The FT IR spectra of compounds 1-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O all 
exhibited indolic (N-H) stretching frequencies at 3350 cm
-1
, 3200 cm
-1
, 3210 cm
-1
, 3229 
cm
-1 
and 3229 cm
-1
, respectively. A comparison between the indolic (N-H) stretching 
frequency observed in the FT IR spectra of compound 1 and [Zn(Sal-L-
tryp)(H2O)].0.25H2O with that of compound 2-4, illustrated a negative shift  upon 
coordination of the “free” thiosemicarbazone ligand to the metal center. 
 The FT IR spectra of all complexes exhibited a (V-S) stretching frequencies at 
455 cm
-1
, 454 cm
-1
, and 455 cm
-1
 for compounds 2, 3, and 4, respectively. The presence 
of (V-S) stretching frequencies in the FT IR spectra of compounds 2-4 confirmed that 
the respective ligands were coordinated to the vanadium metal center via the thiocarbonyl 
sulphur atom.
58
  Similar peaks were absent in the FT IR spectra of the “free” 
thiosemicarbazone ligands.  
 Spectral bands observed in the region 1626 to 1615 cm
-1
 were assigned earlier to 
the (C=N) stretching frequency of the thiosemicarbazone ligand.
148,152,153,156
 Upon 
coordination, however, a significant decrease was observed in the (C=N) stretching
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Table 8   
 
FT IR data for the complexes. 
 
 (A) Compounds 1-4 and Zn(Sal-L-tryp)(H2O)].0.25H2O 
 
  (B) Oxidized products isolated from compounds 1 and 3 
 
 
a – oxidized product obtained from compound 1 
b – oxidized product obtained from compound 3
 
Compound 
Indolic 
(NH) 
/cm-1 
–N1H2  
(NH) 
/cm-1 
N2H  
(NH) 
/cm-1 
  (N-N) 
     /cm-1 
  (C-O) 
/cm-1 
s (COO) 
/cm-1 
as 
(COO) 
/cm-1 
TSC 
(C=N) 
/cm-1 
Sal-L-
tryp 
(C=N) 
/cm-1 
(C=S) 
/cm-1 
(V-S) 
/cm-1 
(V=O) 
/cm-1 
(OH) 
/cm-1 
1 3478 (m) - - - 1540 (m) 1490 (m) 
 
1597 (s) 
- 1600 (m) - - 997 (s) 
3014 
(br) 
2 3200 (m) 
3340 
(m), 
2976 (w) 1148 (m) 1544 (m) 1491 (m) 
 
1600 (s) 
1624 (m) 1590 (m) 1225 (m), 829 (m) 455 (m) 980 (s) - 
3 3210 (m) 3306 (m) 2970 (w) 1154 (m) 1540 (m) 1480 (m) 
 
1600 (s) 
1620 (m) 1580 (m) 1270 (m), 802 (m) 454 (m) 976 (s) 
3010 
(br) 
4 3229 (m) 3310 (m) 2976 (w) 1149 (m) 1545 (m) 1480 (m) 
 
1600 (s) 
1624 (m) 1580 (m) 1287 (m), 819 (m) 455 (m) 982 (s) - 
Zn(Sal-L-
tryp)(H2O)].
0.25H2O 
3405 (m) - - - 1551 (m) 1473 (m) 1597 (s) - 1581 (m) - - - 
3256 
(br) 
Compound 
Indolic 
(NH) 
/cm-1 
  (C-O) 
/cm-1 
s (COO) 
/cm-1 
as (COO) 
/cm-1 
TSC 
(C=N) 
/cm-1 
Sal-L-tryp 
(C=N) 
/cm-1 
(V=O) 
/cm-1 
(OH) 
/cm-1 
(S=O) 
/cm-1 
a [VO(Sal-L-tryp)(DMSO)(OH)] 3185 (m) 1551 (m) 1497 (m) 
 
1618 (s) - 1581 (m) 949 (s) 3194 (br) 
 
1164 (m), 1213 (m)  
b [VO(Sal-L-tryp)(DMSO)(OH)] 3201 (m) 1550 (m) 1497 (m) 
 
1600 (s) 1666 (m) 1590 (m) 946 (s) 3193 (br) 
 
1133 (m), 1157 (m) 
7
9
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frequencies for acetylethTSC (1543 to 1624 cm
-1
 in compound 4) and N-
Ethylmethocarbthio (1606 to 1620 cm
-1
 in compound 3). A significant shift in the 
(C=N) stretching frequency was not evident in the FT IR spectrum of compound 2. 
A decrease in the (C=N) stretching frequency upon coordination of respective 
ligands suggested tha the nitrogen atom (belonging to the -C=N moiety) was involved 
in the ligation process.
128,147,150,152,183-186
 
 A (C=N) stretching frequency attributed to azomethine moiety present in the 
Sal-L-tryp entity of compounds 1-4 were also observed in the respective FT IR spectra. A 
comparison of the respective (C=N) stretching frequencies observed in the FT IR 
spectra of K[(Sal-L-tryp)] with that of compounds 1-4 and [Zn(Sal-L-
tryp)(H2O)].0.25H2O, suggested that this moiety is also in the vicinity of the 
vanadium(IV) metal center. Upon coordination of the respective “free” 
thiosemicarbazone ligands, a shift was observed in the (C=N) stretching frequencies (of 
the Sal-L-tryp moiety) from 1570 cm
-1
 for K[(Sal-L-tryp)] to 1580 cm
-1 
for compounds 3 
and 4, 1600 cm
-1
 for compound 1, 1590 cm
-1
 for compound 2, and 1581cm
-1
 for [Zn(Sal-
L-tryp)(H2O)].0.25H2O.    
  Similarly, the involvement of the thiocarbonyl moiety of the 
thiosemicarbazone ligands in the ligation process was also inferred based on the 
decrease in the (C S) stretching frequencies upon coordination.
128,183,184
 Medium 
intensity spectral bands in the region 841-816 cm
-1
 were earlier assigned to (C S) 
stretching frequency.
152,157,158 
 Upon coordination, a decrease in the order of 12-29 
cm
-1 
was observed in the (C S) stretching frequencies of each complex. The 
magnitude of the shift in the (C S) stretching frequencies confirmed that the 
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thiosemicarbazone ligands  are also coordinated of to the metal center via the neutral 
thioamide sulphur.
128,147,183
 Based on the results presented above, it is evident that the 
neutral, bidentate thiosemicarbazone ligands are coordinated to the vanadium(IV) 
metal center via the nitrogen atom of the -C=N group and the sulphur tom of the 
thiocarbonyl group.
128,183
  
  Broad spectral peaks attributed to (OH) stretching frequencies were observed 
at 3014 cm
-1
, 3010 cm
-1
, and 3256 cm
-1
 for compounds 1 and 3 and [Zn(Sal-L-
tryp)(H2O)].0.25H2O, respectively. The absence of a similar (OH) stretching 
frequencies in the FT IR spectra acquired for compounds 2 and 4 confirmed that the 
Sal-L-tryp moiety was coordinated to the vanadium(IV) metal center via the phenolate 
anion of the respective group.
148,154
 
  All complexes exhibited spectral peaks in the region 997-980 cm
-1
 attributed 
to the (V O) stretching frequencies for typical oxovanadium(IV) 
complexes.
156,184,187
 The (V O) stretching frequencies were observed at 997 cm
-1
, 
980 cm
-1
, 976 cm
-1
, and 982 cm
-1
, for compounds 1, 2, 3, and 4, respectively. 
Subsequent to the coordination of the respective thiosemicarbazone ligands to 
compound 1, a significant decrease in the (V O) stretching frequency occurred, viz., 
17 cm
-1
 in compound 2, 21 cm
-1
 in compound 3, and 15 cm
-1
 in compound 4.  
Oxidized products isolated from Compounds 1 and 3. 
  FT IR spectroscopic data acquired for the oxidized products are shown in 
Table 9 B. Sulphur-containing ligands, such as DMSO, exhibit two potential donor 
sites and are therefore capable of coordinating to metal centers via the oxygen or 
sulphur atom present in the ligand.
188
 Oxygen coordination is favored by smaller, 
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highly charged metal ions whereas heavier metals are known to coordinate via the 
sulphur atom.
188-190
 According to Cotton et al.,
189
 [M(DMSO)2Cl2] (M = Pt and Pd) 
complexes are known to exhibit two strong spectral signals in the regions (1163 to 
1116 cm
-1
) and (1143 to 1117 cm
-1
), attributed to the coordination of the DMSO 
ligand via the sulphur atom.
188
 The FT IR spectra acquired for the oxidized products 
obtained from compounds 1 and 3, both exhibited (S O) stretching frequencies 
assigned to S-bonded DMSO ligand at 1164 and 1213 cm
-1
, and 1133 and 1157 cm
-1
,
 
respectively.  
  Subsequent to aerial oxidation of compounds 1 and 3, a decrease was observed 
in the indolic (N-H) stretching frequency from 3407 cm
-1
 for K[(Sal-L-tryp)] to 3185 
cm
-1
 and 3201 cm
-1
 for the oxidized products obtained from compound 1 and 3, 
respectively. 
  A similar spectral signal attributed to the (C=N) stretching frequency of the 
“free” N-Ethylmethocarbthio ligand was also observed in the FT IR spectrum 
acquired oxidized product obtained from compound 3. This spectral signal, observed 
at 1666 cm
-1
, was assigned to the (C=N) stretching frequency of the displaced “free” 
N-Ethhymethohcarbthio ligand, upon aerial oxidation of compound 3. FT IR 
spectroscopic data therefore confirms that the oxidized product consisted of a mixture 
of the “free” displaced thiosemicarbazone ligand, as well as [VO(Sal-L-
tryp)(DMSO)(OH)].  
  Spectral signals corresponding to (C=N) stretching frequencies of the Sal-L-
tryp moiety were also observed at 1581 cm
-1
 and 1590 cm
-1
 for the products obtained 
from oxidized solutions of compounds 1 and 3, respectively. The FT IR spectra of 
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both oxidzed products also demonstarted an increase in the (V O) stretching 
frequency upon aerial oxidation. Comparison of the respective spectra illustrated a 
shift in the (V O) from  997 cm
-1
 to 949 cm
-1
 for the product obtained from oxidized 
compound 1, and from 976 cm
-1
 to 946 cm
-1
 for the product obtained from oxidized 
compound 3. A broad spectral line attributed to the (OH) stretching frequency was 
also observed at 3194 cm
-1 
and 3193 cm
-1
 for the products obtained from oxidized 
solutions of compounds 1 and compound 3, respectively. 
NMR Spectral Studies 
  NMR spectra were acquired for the oxidized products derived from 
compounds 1 and 3 (see Appendix, Figures A29 and A30) using DMSO-d6 as the 
solvent. Figure 36 shows the lettering system used for the assignments of protons for 
the oxidized complexes (see the experimental section for the lettering in the NMR 
data).  
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Figure 36.  Assignments used for NMR data of complexes in the experimental section. 
 
Both 
1
H NMR spectra acquired for the oxidized products (isolated from compounds 1 
and 3) exhibited broad signals (see Appendix, Figures A24 and A25). These broad 
signal were suggested to be due to the formation of a paramagnetic vanadium(IV) 
species, [VO(Sal-L-tryp)(OH)]
-
, which was identified by ESI MS as discussed above. 
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  The resonance signals most useful for determining the binding mode of DMSO 
was reported to occur at  = 2.7 ppm for O-bonded DMSO and at  = 3.0 - 3.6 ppm  
for S-bonded DMSO.
147
 The absence of a resonance signal at  = 2.7 ppm suggested that 
the DMSO ligand was coordinated via the of sulfur atom and therefore confirms previous 
assignments made in the  FT IR spectroscopic analysis.
147
 The NMR spectra of the 
oxidized products both exhibited a singlet in the region  = 3.0 to 3.6 ppm:  = 3.36 ppm 
for the oxidized product isolated from compound 1 and at  = 3.34 for the product 
isolated from compound 3.  
 The 
1
H NMR spectrum acquired for the oxidized product isolated from precursor 
3 exhibited resonance signals at  = 1.17 ppm and  = 3.79 ppm, assigned to the methyl 
and methylene protons of the “free” N-Ethhymethohcarbthio ligand, respectively. 
Multiplets were also observed in the range  = 6.87 - 7.43 ppm in the spectrum acquired 
for the oxidized product isolated from precursor 3. These resonance signals were 
attributed to the aromatic protons present in the “free” N-Ethhymethohcarbthio ligand 
and the oxidized complex.  
 The 
1
H NMR spectrum acquired for the oxidized product isolated from compound 
1 exhibited resonance signals in the region  = 7.06 to 7.52 ppm, which were assigned to 
aromatic protons of the oxidized product. Resonance signals attributed azomethine proton 
of the indole ring present in the L-tryptophan moiety were also observed at in the region  
= 7.82 to 8.09 ppm, and  = 7.06 to 10.43 ppm, for the oxidized products isolated from 
compound 1 and compound 3, respectively. In the 
1
H NMR spectrum acquired for the 
oxidized product isolated from compound 3, the previously mentioned resonance signal 
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was suggested to be overlapped with the signal attributed to the N(2)-H proton of the  
“free” N-Ethhymethohcarbthio ligand. 
UV-Visible and Fluorescence Spectroscopic Studies of Compound 1-4 
  UV-visible spectral data were acquired for compounds 1-4 using DMSO as 
solvent. The respective UV-visible spectra acquired for compounds 1-4 are shown in 
figures 36-39 (See Appendix, Figures A31-A33), and the assignments are shown in 
Table 9. The UV-Visible spectra acquired for compounds 2-4 all exhibited charge 
transfer bands in the region 266-292 nm, assigned to π→π* transitions associated 
with the thioamide moiety. 
152,154
 These spectral bands were observed at 266 nm and 
292 nm (shoulder) for compound 2, at 270 nm and 288 nm (both as shoulders) for 
compound 3, and at 276 nm for compound 4. Previous spectroscopic studies has 
proven that charge transfer bands attributed to n→π* transitions of aromatic rings 
usually exist in the region 316-352 nm.
152,154,184,191,192
 Similar spectral bands were 
also observed in the UV-Vis spectra of compounds 2-4. The respective bands were 
observed as a shoulder at 316 nm for compound 2, at 330 nm for compound 3, and 
352 nm for compound 4. 
  According to Cavaco et al.,
60 
oxovanadium(IV) complexes derived from 
salicylaldehyde ligands are known to exhibit a low-energy spectral band around 375 
nm, attributed to π→π* transitions associated with the azomethine chromophore.60 
Similar spectral bands were also observed at 388 nm for compound 2, as a shoulder at 
390 nm for compound 3 and hidden beneath the n→π* transition for compound 4. The 
UV-Visible spectra acquired for compounds 1-4 all exhibited spectral bands in the 
region 550-558 nm, attributed to p→d LMCT transitions (where p represents the lone  
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Figure 37.  A UV-visible spectrum of compound 1 in DMSO. 
 
 
 
Figure 38.  A UV-visible spectrum of compound 2 in DMSO. 
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Figure 39.  A UV-visible spectrum of compound 3 in DMSO. 
 
 
 
Figure 40.  A UV-visible spectrum of compound 4 in DMSO. 
 
 
88 
  
 
 
Table 9   
UV-visible spectral data for compounds 1-4. 
 
 
Complex 
 
/nm /M
-1
cm
-1
 
 
Assignments 
 
1 
 
558 
758 
 
44 
27 
 
LMCT  (p → d transition) 
d → d transition  
 
2 
 
266 
292 (sh) 
316 (sh) 
388 
550 
592 (sh) 
756 
74835 
17954 
10046 
15013 
54 
45 
28 
π → π* (thioamide moiety) 
π → π* (thioamide moiety) 
n → π* (aromatic rings) 
π → π* (azomethine chromophore) 
LMCT  (p → d transition) 
d → d transition  
d → d transition 
 
3 
270 (sh) 
288 (sh) 
330 
390 (sh) 
620 
10984 
13874 
24837 
18250 
852 
π → π* (thioamide moiety) 
π → π* (thioamide moiety) 
n → π* (aromatic rings) 
π → π* (azomethine chromophore) 
d → d transition 
 
4 
276 
352 
558 
590 (sh) 
756 
21969 
14227 
80 
70 
38 
π → π* (thioamide moiety) 
n → π* (aromatic rings) 
LMCT  (p → d transition) 
d → d transition  
d → d transition  
 
 
pair of electrons on the  phenolato oxygen, and d represents the 3d orbitals of the 
vanadium metal center).
193,194
 Similar spectral bands were observed at 558 nm for 
compound 1, 550 nm for compound 2, and 558 nm for compound 4. A similar spectral 
band was absent in the UV-Visible spectrum acquired for compound 3 since it is believed 
to be hidden under the spectral band assigned to d→d transitions.  
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 According to Pessoa et al., the UV-Visible spectral bands observed in the region 
756-758 nm are attributed to d-d transitions of the metal center.
187
 In our case, similar 
spectral bands were observed at 758 nm for compound 1 and at 756 nm for compounds 2 
and 4.  Spectral bands assigned to d→d transitions also appeared as shoulders (of the 
much stronger LMCT band in the region 550-558 nm) at 592 nm and 590 nm for 
compounds 2 and 4, respectively. 
  Fluorescence spectral data were acquired for compounds 2-4 in DMSO (see 
appendix, Figures A26-A28). Compounds 2, 3, and 4 were excited at 400, 330, and 
340 nm, respectively. The highest fluorescence intensity was observed in the 
fluorescence spectrum of compound 2 due to the presence of an anthracene moiety in 
the MEATSC ligand while compounds 3 and 4 produced the lower intensities. 
Electrochemical Studies 
Compounds 1-4 and [Zn(Sal-L-tryp)(H2O)].0.25H2O. CV and square wave 
voltammograms were acquired for Compound 1-4 and [Zn(Sal-L-
tryp)(H2O)].0.25H2O as shown in figures 40 and 41 (see Appendix, Figures A34 and 
A35). The data collected from electrochemical studies are shown in Table 10. The 
Zn(II) metal center is known to be redox inactive.
195
 Electrochemical data acquired 
for [Zn(Sal-L-tryp)(H2O)].0.25H2O was therefore used to confirm the electrochemical 
data due to metal-based electron transfer in compounds 1-4.  
  An irreversible anodic redox peak attributed to the oxidation of the L-  
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Figure 41.  A cyclic voltammogram of a 1.0 mM solution of [Zn(Sal-L-
tryp)(H2O)].0.25H2O in DMSO. Electrodes: platinum working electrode, platinum 
auxiliary electrode and Ag/Ag
+
 (0.01 M AgNO3 and 0.10 M TBAP in acetonitrile) 
reference electrode. Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s
-1
. 
 
 
 
Figure 42.  Cyclic voltammograms of 1.0 mM solutions of compounds 1-4 in DMSO. 
Electrodes: platinum working electrode, platinum auxiliary electrode and Ag/Ag
+
 (0.01 
M AgNO3 and 0.10 M TBAP in acetonitrile) reference electrode. Supporting electrolyte = 
0.1 M TBAP. Scan rate = 100 mV s
-1
. 
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Table 10  
 
Electrochemical data of 1.0 mM solutions of compounds 1-4, product isolated from 
oxidized compound 1, and [Zn(Sal-L-tryp)(H2O)].0.25H2O in DMSO.  
 
A) Compounds 1-4 
 
Species 
 
 
E/V 
 
 
Assignment 
 
1 
 
Epa  =  +0.71 
Epa   =  +0.22 
Epa   =  -0.78 
Epa   =  -1.28 
Epc   =  -0.88 
Epc   =  -1.57 
 
L-tryp
0/+
 
V
IV/V 
V
III/IV 
- 
V
IV/III 
L-tryp
+/0 
 
2 Epa  =  +0.87 
Epa  =  +0.73 
Epa   =  +0.21 
Epa   =  -0.78 
Epa   =  -1.24 
Epc   =  -0.89 
Epc   =  -1.57 
 
Oxidation of anthracene moiety 
L-tryp
0/+
 
V
IV/V 
V
III/IV 
CH2-NH/ HC=N 
V
IV/III 
L-tryp
+/0
 
3 Epa  =  +0.81 
Epa   =  +0.64 
Epa   =  +0.43 
Epa   =  +0.21 
Epa   =  -0.16 
Epa   =  -1.07 
Epa   =  -1.36 
Epc   =  -0.34 
Epc   =  -0.88 
Epc   =  -1.17 
Epc   =  -1.65 
- 
L-tryp
0/+
 
Oxidation of  phenolate in vanillin moiety 
V
IV/V 
- 
V
III/IV 
CH2-NH/ HC=N  
- 
V
IV/III 
- 
L-tryp
+/0 
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Table 10 (continued). 
 
 
Species 
 
 
E/V 
 
 
Assignment 
 
4 
 
Epa  =  +0.82 
Epa   =  +0.66 
Epa   =  +0.21 
Epa   =  -0.12 
Epa   =  -1.07 
Epa   =  -1.31 
Epa   =  -1.67 
Epc   =  -0.68 
Epc   =  -0.92 
Epc   =  -1.13 
Epc   =  -1.51 
 
- 
L-tryp
0/+
 
V
IV/V 
- 
V
III/IV 
CH2-NH/ HC=N  
- 
- 
V
IV/III 
- 
L-tryp
+/0 
 
 
 
 B) Oxidized product obtained from compound 1 and [Zn(Sal-L-
 tryp)(H2O)].0.25H2O. 
 
Species 
 
 
E/V 
 
 
Assignment 
 
Oxidized Compound 1 
 
Epa  =  +0.66 
Epa   =  +0.22 
Epa   =  -0.12 
Epa   =  -1.06 
Epa   =  -1.39 
Epa   =  -1.66 
Epc   =  -0.17 
Epc   =  -0.48 
Epc   =  -0.96 
Epc   =  -1.15 
Epc   =  -1.30 
Epc   =  -1.50 
 
L-tryp
0/+
 
V
IV/V 
- 
V
III/IV 
- 
- 
- 
- 
V
IV/III 
- 
V
V/IV 
L-tryp
+/0
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Table 10 (continued). 
 
 
Species 
 
 
E/V 
 
 
Assignment 
   
[Zn(Sal-L-tryp)(H2O)].0.25 H2O Epa  =  +0.71 
Epa   =  +0.59 
Epa   =  -0.67 
Epa   =  -1.34 
Epc   =  -0.84 
Epc   =  -1.30 
Epc   =  -1.59 
L-tryp
0/+
 
PhO
-/. 
- 
- 
- 
- 
L-tryp
+/0 
 
 
Note. Electrodes: platinum working electrode, platinum auxiliary electrode and Ag/Ag+ (0.01 M AgNO3 and 0.10 M TBAP in 
acetonitrile) reference electrode. Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s-1. 
 
tryptophan moiety of the Schiff base ligand (salicylaldehyde) was observed in the CV 
of each complex. Upon coordintion of the Schiff base ligand (salicylaldehyde moiety) 
to the respective metal center, a decrease in the redox potential attributed to the 
oxidation of the L-tryptophan moiety was generally observed. This redox potential 
decreased from +0.75 V in K[(Sal-L-tryp)] to +0.71 V for [Zn(Sal-L-
tryp)(H2O)].0.25H2O and compound 1, to +0.73 V for compound 2, to +0.64 V for 
compound  3, and to +0.66 V for compound 4. The respective aniodic redox peaks 
were also confirmed using square wave voltammetry. The square voltammograms 
(see Appendix, Figures A38 and A39) of all complexes exhibited anodic redox peaks 
at +0.70 V for [Zn(Sal-L-tryp)(H2O)].0.25H2O, at +0.67 V for compounds 1, 2, and 3, 
and at +0.62 V for compound 4. These redox peaks were all attributed to the oxidation 
of the L-tryptophan moiety. 
  The CV acquired for [VO(salen)] exhibited an irreversible anodic redox peak 
at +0.50 V, attributed to the V(IV)/V(V) redox couple as reported by Kianfar and 
Mohebbi.
196
 According to Maia et al.,
197
 electrochemical data acquired for V(IV) 
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complexes were also shown to exhibit irreversible anodic redox peaks in the region 
+0.60 V to +0.65 V, attributed to the V(IV)/V(V) redox couple.
197
 Similar redox 
peaks attributed to the V(IV)/V(V) redox couple were also observed in the CV’s 
acquired for our complexes. The irreversible anodic redox peaks attributed to the 
V(IV)/V(V) redox couple were observed at +0.22 V for compound 1 and at +0.21 V 
for compounds 2-4. Redox peaks attributed to the V(IV)/V(V) redox couple were 
observed at +0.18 V for compounds 1 and 3 and at +0.17 V in the square wave 
voltammograms of compounds 2 and 4.  
  CV acquired for oxovanadium(IV) complexes are also known to display 
cathodic quasi-reversible voltammetric responses attributed to the V(IV)/V(III) redox 
couple in the potential range -0.9 V to -1.3 V.
191
 In our case, simiar cathodic quasi-
reversible redox peaks were observed at -0.88 V, -0.89 V, -0.88 V and -0.92 for 
compounds 1, 2, 3, and 4, respectively. The corresponding anodic quasi-reversible 
redox peak were observed at -0.78 V for compounds 1 and 2 and at -1.07 V 
compounds 3 and 4. All other cathodic peaks observed in the voltammograms 
acquired for each complex were assigned to the reduction of cation radicals  
  Oxidized products isolated from Compounds 1. The representative CV and 
square wave voltammogram acquired for the product isolated from the oxidized 
solution of compound 1 is shown in figures 43 and 44. Products obtained from 
oxidized DMSO solutions of compounds 2-4 are proposed to exhibit similar 
electrochemical properties.  
95 
  
 
 
 
Figure 43.  A cyclic voltammogram of a 1.0 mM solution of the oxidized product 
isolated from compound 1 in DMSO. Electrodes: platinum working electrode, platinum 
auxiliary electrode and Ag/Ag
+
 (0.01 M AgNO3 and 0.10 M TBAP in acetonitrile) 
reference electrode. Supporting electrolyte = 0.1 M TBAP. Scan rate = 100 mV s
-1
. 
 
 
Figure 44.  A square wave voltammogram: The oxidation of a 1.0 mM solution of the 
oxidized product isolated from compound 1 in DMSO. Electrodes: platinum working 
electrode, platinum auxiliary electrode and Ag/Ag
+
 (0.01 M AgNO3 and 0.10 M TBAP in 
acetonitrile) reference electrode. Supporting electrolyte = 0.1 M TBAP. Initial potential = 
0 V, final potential = +1.0 V, step E = 4 mV, S.W. amplitude = 25 mV, S.W. frequency = 
15 Hz, filter = 100 Hz, and quiet time = 2 s. 
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Anodic redox peaks attributed to the oxidation of the L-tryptophan moiety, were 
observed at +0.66 V and at +0.63 V in the CV and square wave voltammogram (of the 
product isolated from the oxidized solution of compound 1), respectively. Redox 
couples were observed at +0.22 V and 0.18 V in the CV and square wave 
voltammogram, respectively.  The observance of a redox peak corresponding to the 
V(IV)/V(V) redox couple suggested that the product isolated from the oxidized 
solution of compound 1 was actually a mixture V(IV) and V(V) species. The CV of 
this oxidized product also exhibited a quasi-reversible redox wave (Epc   =  -0.96 V 
and Epa   =  -1.06 V) attributed to the V(IV)/V(III) redox couple.
191
 
In vitro Studies 
  The data aquired from in vitro studies are presented in Table 11. The aim of 
these in vitro studies is to evaluate the antiproliferative activity of compounds 1-4 
against colon cancer cell lines (HTC-116, Caco-2, and HT-29) and to compare the 
anti-proliferative activity with that of one non-cancerous colon cell line (CCD18-Co).  
Colorimetric assay (MTS assay), a technique that measures mitochondrial 
dehydrogenase activity as an indication of cell viability was used to evaluate the 
cytotoxicity of compounds 2-4 on three different cancer colon cell lines (HCT116, 
Caco-2 and HT-29). The effects of the compounds on the viability of these cells were 
evaluated after continuous incubation (24, 48, and 72 hours).   
  A  comparison between the growth inhibition effect of the respective 
compounds against non-cancerous colonic myofibroblasts CCD-18Co cells and cancer 
colon cell lines were investigated. The results indicated a large difference in the 
inhibition of cell proliferation between cancer lines and the non-cancerous CCD-18Co  
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Table 11   
Anti-proliferative effects of compounds 2-4, cisplatin, and etoposide on different cells 
lines after 24, 48 and 72 hours treatment.   
 
 
 
Species 
   
                      HT-29  
24 hrs             48 hrs          72 hrs 
 
                      Caco-2 
24 hrs             48 hrs          72 hrs 
 
 
IC50/ M IC50/ M IC50/ M IC50/ M IC50/ M IC50/ M 
 
2 
 
 
277.1±10.2 
 
239.6±7.9 
 
100.3±5.1 
 
349.1±19.
5 
 
277.1±16.3 
 
147.1±10.8 
3 244.2±8.8 169.6±15.
1 
87.9±0.5 367.0±21.
5 
281.6±14.4 152.5±12.7 
4 128.6±10.7 82.4±9.6 47.8±5.5 242.1±25.
1 
166.2±15.3 85.4±14.0 
Cisplatin 84.7±1.9 80.6±1.6 69.1±3.2 32.0±1.6 22.8±1.5 17.9±1.8 
Etoposide 19.2±0.8 17.3±1.9 15.8±2.4 47.6±0.8 46.2±1.9 40.9±1.5 
 
Species 
                    HCT-116 
24 hrs             48 hrs           72 hrs 
 
                    CCD-18Co 
24 hrs             48 hrs           72 hrs 
 
IC50/ M IC50/ M IC50/ M IC50/ M IC50/ M IC50/ M 
2 203.4±7.7 181.3±9.2 115.0±6.5 495.6±23.5 339.2±16.7 208.0±11.9 
3 227.4±6.8 192.7±11.6 110.3±10.1 490.6±27.6 329.5±15.4 203.6±12.5 
4 161.3±4.6 134.9±3.9 89.5±14.5 382.7±21.9 246.2±11.4 152.2±12.0 
Cisplatin 53.8±2.1 49.7±1.3 41.0±2.7 83.0±1.1 72.0±1.5 64.1±1.6 
Etoposide 40.8±0.5 36.2±2.0 38.4±1.2 82.5±3.1 79.2±1.2 73.2±1.9 
 
cells. The growth inhibition effect of the respective compounds were shown to be 
time dependent as shown in Table 11.  
  Compounds 2-4 have been shown to time-dependently decrease cell viability 
of HCT-116, Caco-2, and more potently, in HT-29 cells (Table 11). While compounds 
2 and 3 showed similar activities in both cancer cell lines, compound 4 was shown to 
be the most active of the three compounds tested. A plot of percentage cell viability 
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versus concentration of compound 4 against the HT-29 cancer cell line were plotted 
as shown in Figure 45 while the IC50 values for inhibition of cell proliferation for 
compounds 2-4. After 72 hours, the IC50 values for compounds 2 and 3 were generally 
around 100 M concentration. Although our compounds did not exhibit better 
efficacy against any of the cancer cell lines when compared to etoposide, compound 4 
was shown to have a better efficacy on the HT-29 cancer cell line when compared to 
cisplatin (Table 11). 
   The possibility of cytotoxic selectivity towards colon cancer cells is suggested  
since all three compounds exhibited less inhibitory effects in human normal CCD- 
 
 
 
Figure 45. MTT cell proliferation assay of compound 4 against the HT-29 cancer cell 
line. 
 
18Co cells. The IC50 values obtained for CCD-18Co were observed to be 3-fold and 2-
fold than HT-29 and Caco-2 and HCT-116, respectively. The cytotoxic selectivity of 
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cisplatin (a positive control) towards the cancer colon cells (except on Caco-2 cells) was 
observed to be slightly lower than our synthesized compounds (Table 11). Cisplatin was 
previously reported to inhibit cell proliferation by about 70% in both cell lines (cancer 
and normal colon cells).
198
 Overall, due to the fact that compounds 2-4 had no effect on 
non-cancerous cells but exhibited properties of potential growth suppressors of cancer 
cells, these compounds are proposed to be potential chemotherapeutic agents.  
  Although metal complexes are currently being investigated as probes and 
therapeutics, the various pathways and uptake mechanisms for metal complexes into 
cells are are sparse in literature.  A review of the cellular accumulation of cisplatin 
has recently been reported.
199,200
 Platinum-containing drugs are capable of entering 
the cell by passive diffusion, by organic cation transporters, by the copper transporter 
Ctr1, and possibly by endocytosis.
200
 Ruthenium(II) complex containing lipophilic 
cations, for example the lipophilic 4,7-diphenyl-1,10-phenanthroline ligand, has been 
shown to passively diffuse across the plasma membrane in a membrane-potential 
dependent manner.
200
 The excellent efficacy of the ruthenium(II) complexes with 
thiosemicarbazones as reported in a study by Beckford and co-workers
128
 is also 
suggested to be due to the lipophilic nature of the respective complexes.  Similarly, 
lipophilic cations, such as [(bpy)2Ru(thiosemicarbazone)](PF6)2 and 
[(phen)2Ru(thiosemicarbazone)](PF6)2 (where thiosemicarbazone = 9-
anthraldehydethiosemicarbazone, 9-anthraldehyde-N(4)-methylthiosemicarbazone, 
and 9-anthraldehyde-N(4)-ethylthiosemicarbazone),
128
 are also observed  to have 
better efficacies against HT-29 and HCT-116 cell lines versus our neutral 
vanadium(IV) complexes for similar reasons. 
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  In order to accurately conclude, a systematic study of ruthenium(II) complexes 
and compounds 2-4, all under the same conditions, is needed. Apart from such a 
study, a more detailed emphasis will be placed on the methods used to examine 
cellular accumulations in order to identify the mechanism(s) of uptake, and to monitor 
possible efflux compounds 2-4, and their analogues in the near future.
201
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CHAPTER IV 
CONCLUSIONS AND FUTURE WORK 
Conclusions 
 Two novel thiosemicarbazone ligands, MeATSC and N-Ethhymethohcarbthio 
were successfully synthesized and characterized. A reduced Schiff base and K[Sal-L-
tryp)] ligand was also synthesized and characterized. Each thiosemicarbazone ligand was 
then coordinated to [VO(Sal-L-tryp)] (1) to form three novel V(IV) complexes. 
Thiosemicarbazones are known to exhibit thione-thiol tautomerism and can coordinate to 
metal centers either as a neutral (thione) or as a mono-anionic (thiolate) ligand. Due to 
the absence of a ((S-H) spectral band in the FT IR spectra, the ligands were said to exist 
as neutral (thione) ligands.  
  Upon aerial oxidation, DMSO solutions of compounds 1-4 were readily oxidized 
to form V(V) species. All compounds are believed to behave similarly; hence, for this 
study, we focused on compounds 1 and 3 only. ESI MS data was used to identify the 
species formed in solution upon oxidation. The proposed mechanism (Scheme 14) 
suggests that the ligands are first substituted by DMSO solvent molecules followed by 
the dimerization of the solvated complexes to form binuclear species. 
 In this study, all four V(IV) compounds were shown to exhibit anti-cancer effects 
against three colon cancer cell lines, HTC-116, Caco-2, and HT-29. A comparative anti-
proliferative study on non-cancerous colonic myofibrolasts, CCD18-Co, indicated that 
our novel compounds had no effect on these non-cancerous colorectal cells. The novel 
V(IV) compounds were also shown to exhibit cytotoxic selectivity towards colon cancer 
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cells. Cytotoxic selectivity was evident since compounds 2-3 exhibited less inhibitory 
effects in human non-cancerous CCD-18Co cells.  
 Overall, although compounds 1-4 are relatively unstable, compounds 2-3 
exhibited interesting anti-proliferative activity on colon cancer cells. Due to existence of 
several species in solution (upon oxidation), the identity of the active species still remains 
unclear. A thorough investigation is therefore needed in order to identify the active 
species responsible for anti-proliferative activity. We are therefore suggesting that these 
compounds might be effective as chemotherapeutic agents.  
Future Work 
 The synthesis and characterization of these novel thiosemicarbazone ligands and 
V(IV) compounds has paved the way for a series of interesting research with similar 
compounds. These compounds were shown to exhibit anti-cancer activity against colon 
cancer cell lines. This area of research can be expanded by synthesizing a series of 
similar V(IV) complexes containing varying thiosemicarbazone ligands. It is also 
important to investigate the effect of varying thiosemicarbazone ligands on the stability 
of the respective complexes.  
 During this study compounds 1-4 were shown to be readily oxidized to V(V) 
species upon aerial oxidation.  The question as to the identity of the species solely 
responsible for antiproliferative activity is therefore asked.  ESI MS data has provided 
information allowing us to formulate a proposed mechanism for the identity of the 
species formed upon oxidation. An in depth study is therefore needed in order to confirm 
the identity of the oxidized species and to study the relative stability and anti-proliferative 
effects of such oxidized species.    
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APPENDIX A 
A MASS SPECTRUM OF THE REDUCED SCHIFF BASE (2-(2-
HYDROXYBENZYLAMINO)-3-(1H-INDOL-3-YL)PROPANOIC ACID) IN THE 
POSITIVE MODE 
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APPENDIX B 
A MASS SPECTRUM OF K[(Sal-L-tryp)] IN THE POSITIVE MODE 
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APPENDIX C 
AN FT IR SPECTRUM OF MEATSC 
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APPENDIX D 
AN FT IR SPECTRUM OF N-ETHHYMETHOHCARBTHIO 
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APPENDIX E 
AN FT IR SPECTRUM OF ACETYLETHTSC 
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APPENDIX F 
FT IR SPECTRUM OF THE REDUCED SCHIFF BASE 
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APPENDIX G 
AN FT IR SPECTRUM OF K[(Sal-L-tryp)] 
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APPENDIX M 
A SQUARE WAVE VOLTAMMOGRAM.  THE OXIDATION OF A 1.0 MM 
SOLUTION OF K[(Sal-L-tryp)] IN DMSO. ELECTRODES: PLATINUM WORKING 
ELECTRODE, PLATINUM AUXILIARY ELECTRODE AND Ag/Ag
+
 (0.01 M AgNO3 
AND 0.10 M TBAP IN ACETONITRILE) REFERENCE ELECTRODE. SUPPORTING 
ELECTROLYTE = 0.1 M TBAP. INITIAL POTENTIAL = 0 V, FINAL POTENTIAL = 
+1.0 V, STEP E = 4 mV, S.W. AMPLITUDE = 25 mV, S.W. FREQUENCY = 15 Hz, 
filter = 100 Hz, AND QUIET TIME = 2 s 
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APPENDIX N 
SQUARE WAVE VOLTAMMOGRAMS: THE OXIDATION OF 1.0 MM 
SOLUTIONS OF THIOSEMICARBAZONE LIGANDS IN DMSO. ELECTRODES: 
PLATINUM WORKING ELECTRODE, PLATINUM AUXILIARY ELECTRODE 
AND Ag/Ag
+
 (0.01 M AgNO3 AND 0.10 M TBAP IN ACETONITRILE) REFERENCE 
ELECTRODE. SUPPORTING ELECTROLYTE = 0.1 M TBAP. INITIAL POTENTIAL 
= 0 V, FINAL POTENTIAL = +1.0 V, STEP E = 4 mV, S.W. AMPLITUDE = 25 mV, 
S.W. FREQUENCY = 15 Hz, FILTER = 100 Hz, AND QUIET TIME = 2 s 
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APPENDIX O 
A MASS SPECTRUM OF COMPOUND 2 IN THE POSITIVE MODE 
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APPENDIX P 
A MASS SPECTRUM OF COMPOUND 3 IN THE NEGATIVE MODE 
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APPENDIX Q 
A MASS SPECTRUM OF COMPOUND 4 IN THE POSITIVE MODE 
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APPENDIX R 
A MASS SPECTRUM OF [Zn(Sal-L-tryp)(H2O)].0.25H2O IN THE POSITIVE MODE 
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APPENDIX S 
A MASS SPECTRUM OF OXIDISED PRODUCT ISOLATED FROM COMPOUND 1 
IN THE POSITIVE MODE 
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APPENDIX T 
A MASS SPECTRUM OF OXIDIZED PRODUCT ISOLATED FROM COMPOUND 1 
IN THE NEGATIVE MODE 
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APPENDIX U 
A MASS SPECTRUM OF OXIDIZED PRODUCT ISOLATED FROM COMPOUND 3 
IN THE POSITIVE MODE 
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APPENDIX V 
 
A MASS SPECTRUM OF OXIDIZED PRODUCT ISOLATED FROM COMPOUND 3 
IN THE NEGATIVE MODE 
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APPENDIX W 
AN FT IR SPECTRUM OF COMPOUND 
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APPENDIX X 
AN FT IR SPECTRUM OF COMPOUND 2 
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APPENDIX Y 
AN FT IR SPECTRUM OF COMPOUND 3 
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APPENDIX Z 
AN FT IR SPECTRUM OF COMPOUND 4 
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APPENDIX AA 
AN FT IR SPECTRUM OF [Zn(Sal-L-tryp)(H2O)].0.25H2O 
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APPENDIX EE 
UV-VISIBLE AND FLUORESCENCE SPECTRA FOR A 20 M SOLUTION OF 
COMPOUND 2 IN DMSO.  EXCITATION WAVELENGTH  = 400 nm 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
APPENDIX FF 
UV-VISIBLE AND FLUORESCENCE SPECTRA FOR A 20 M SOLUTION OF 
COMPOUND 3 IN DMSO.  EXCITATION WAVELENGTH  = 330 nm  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
APPENDIX GG 
 
UV-VISIBLE AND FLUORESCENCE SPECTRA FOR A 20 M SOLUTION OF 
COMPOUND 4 IN DMSO.  EXCITATION WAVELENGTH  = 340 nm  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
APPENDIX HH 
SQUARE WAVE VOLTAMMOGRAMS: THE OXIDATION OF 1.0 mM 
SOLUTIONS COMPOUNDS 1-4 IN DMSO. ELECTRODES: PLATINUM WORKING 
ELECTRODE, PLATINUM AUXILIARY ELECTRODE AND Ag/Ag+ (0.01 M 
AgNO3 AND 0.10 M TBAP IN ACETONITRILE) REFERENCE ELECTRODE. 
SUPPORTING ELECTROLYTE = 0.1 M TBAP. INITIAL POTENTIAL = 0 V, FINAL 
POTENTIAL = +1.0 V, STEP E = 4 mV, S.W. AMPLITUDE = 25 mV, S.W. 
FREQUENCY = 15 Hz, FILTER = 100 Hz, AND QUIET TIME = 2 s 
 
 
 
 
 
  
 
APPENDIX II 
A SQUARE WAVE VOLTAMMOGRAM: THE OXIDATION OF A 1.0 MM 
SOLUTION [Zn(Sal-L-tryp)(H2O)].0.25H2O IN DMSO. ELECTRODES: PLATINUM 
WORKING ELECTRODE, PLATINUM AUXILIARY ELECTRODE AND Ag/Ag+ 
(0.01 M AgNO3 AND 0.10 M TBAP IN ACETONITRILE) REFERENCE 
ELECTRODE. SUPPORTING ELECTROLYTE = 0.1 M TBAP. INITIAL POTENTIAL 
= 0 V, FINAL POTENTIAL = +1.0 V, STEP E = 4 mV, S.W. AMPLITUDE = 25 mV, 
S.W. FREQUENCY = 15 Hz, FILTER = 100 Hz, AND QUIET TIME = 2 s 
 
 
 
 
 
 
 
 
 
 
 
  
 
APPENDIX JJ 
ATOMIC COORDINATES (x 10
4
) AND EQUIVALENT ISOTROPIC 
DISPLACEMENT PARAMETERS (A
2
 x 10
3
) FOR VENKAT35.  U(eq) IS DEFINED 
AS ONE THIRD OF THE TRACE OF THE ORTHOGONALIZED Uij TENSOR 
________________________________________________________________ 
 
x             y             z           U(eq) 
________________________________________________________________ 
 
S(1)         7608(1)       4402(1)       4836(1)       26(1) 
S(2)         3123(1)       4067(1)       7194(1)       23(1) 
N(1)         5081(1)       3382(1)       6207(1)       20(1) 
N(2)         6001(1)       3320(1)       5703(1)       21(1) 
N(3)         6006(1)       5421(1)       5737(1)       20(1) 
N(4)         3033(2)       1718(1)       7328(1)       30(1) 
C(1)         6484(2)       4402(2)       5460(1)       19(1) 
C(2)         4599(2)       2389(2)       6452(1)       24(1) 
C(3)         3608(2)       2598(2)       6982(1)       23(1) 
C(4)         2174(2)       2220(2)       7788(1)       31(1) 
C(5)         2091(2)       3456(2)       7789(1)       27(1) 
C(6)         4934(2)       1099(2)       6252(1)       41(1) 
C(7)         6390(2)       6658(2)       5541(1)       23(1) 
C(8)         5569(2)       7599(2)       5915(1)       27(1) 
________________________________________________________________ 
  
 
APPENDIX KK 
BOND LENGTHS [Å] AND ANGLES [°] FOR VENKAT35 
_____________________________________________________________ 
 
S(1)-C(1)                     1.6814(16) 
S(2)-C(5)                     1.7094(17) 
S(2)-C(3)                     1.7282(17) 
N(1)-C(2)                     1.284(2) 
N(1)-N(2)                     1.3691(18) 
N(2)-C(1)                     1.366(2) 
N(2)-H(2N)                    0.86(2) 
N(3)-C(1)                     1.329(2) 
N(3)-C(7)                     1.457(2) 
N(3)-H(3N)                    0.81(2) 
N(4)-C(3)                     1.312(2) 
N(4)-C(4)                     1.376(2) 
C(2)-C(3)                     1.474(2) 
C(2)-C(6)                     1.498(2) 
C(4)-C(5)                     1.349(3) 
C(4)-H(4)                     0.9500 
C(5)-H(5)                     0.9500 
C(6)-H(6A)                    0.9800 
C(6)-H(6B)                    0.9800 
C(6)-H(6C)                    0.9800 
C(7)-C(8)                     1.521(2) 
C(7)-H(7A)                    0.9900 
C(7)-H(7B)                    0.9900 
C(8)-H(8A)                    0.9800 
C(8)-H(8B)                    0.9800 
C(8)-H(8C)                    0.9800 
 
C(5)-S(2)-C(3)               89.03(8) 
C(2)-N(1)-N(2)              119.74(14) 
C(1)-N(2)-N(1)              117.46(13) 
C(1)-N(2)-H(2N)             118.7(13) 
N(1)-N(2)-H(2N)             123.5(13) 
C(1)-N(3)-C(7)              124.42(14) 
C(1)-N(3)-H(3N)             117.4(15) 
C(7)-N(3)-H(3N)             118.1(15) 
C(3)-N(4)-C(4)              109.59(15) 
N(3)-C(1)-N(2)              116.37(14) 
N(3)-C(1)-S(1)              123.34(12) 
N(2)-C(1)-S(1)              120.29(12) 
N(1)-C(2)-C(3)              113.65(14) 
  
 
N(1)-C(2)-C(6)              127.15(15) 
C(3)-C(2)-C(6)              119.19(14) 
N(4)-C(3)-C(2)              124.04(15) 
N(4)-C(3)-S(2)              114.99(12) 
C(2)-C(3)-S(2)              120.97(12) 
C(5)-C(4)-N(4)              116.11(16) 
C(5)-C(4)-H(4)              121.9 
N(4)-C(4)-H(4)              121.9 
C(4)-C(5)-S(2)              110.27(13) 
C(4)-C(5)-H(5)              124.9 
S(2)-C(5)-H(5)              124.9 
C(2)-C(6)-H(6A)             109.5 
C(2)-C(6)-H(6B)             109.5 
H(6A)-C(6)-H(6B)            109.5 
C(2)-C(6)-H(6C)             109.5 
H(6A)-C(6)-H(6C)            109.5 
H(6B)-C(6)-H(6C)            109.5 
N(3)-C(7)-C(8)              110.14(14) 
N(3)-C(7)-H(7A)             109.6 
C(8)-C(7)-H(7A)             109.6 
N(3)-C(7)-H(7B)             109.6 
C(8)-C(7)-H(7B)             109.6 
H(7A)-C(7)-H(7B)            108.1 
C(7)-C(8)-H(8A)             109.5 
C(7)-C(8)-H(8B)             109.5 
H(8A)-C(8)-H(8B)            109.5 
C(7)-C(8)-H(8C)             109.5 
H(8A)-C(8)-H(8C)            109.5 
H(8B)-C(8)-H(8C)            109.5 
_____________________________________________________________ 
 
Symmetry transformations used to generate equivalent atoms: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
APPENDIX LL 
ANISOTROPIC DISPLACEMENT PARAMETERS (A
2
 x 10
3
) FOR VENKAT35.  THE 
ANISOTROPIC DISPLACEMENT FACTOR EXPONENT TAKES THE FORM: -2 
2
 
[ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ] 
__________________________________________________________________ 
              U11        U22        U33        U23        U13        U12     
__________________________________________________________________  
    
    S(1)     25(1)      18(1)      37(1)       3(1)      18(1)       0(1)  
    S(2)     30(1)      14(1)      28(1)       1(1)      13(1)       1(1)  
    N(1)     23(1)      18(1)      21(1)       1(1)       9(1)      -1(1)  
    N(2)     24(1)      14(1)      24(1)      -1(1)      12(1)       0(1)  
    N(3)     20(1)      16(1)      25(1)       2(1)      10(1)      -2(1)  
    N(4)     38(1)      17(1)      37(1)       1(1)      23(1)       0(1)  
    C(1)     17(1)      18(1)      22(1)       1(1)       3(1)      -1(1)  
    C(2)     30(1)      16(1)      27(1)      -1(1)      13(1)       0(1)  
    C(3)     29(1)      13(1)      28(1)       0(1)      13(1)       1(1)  
    C(4)     39(1)      20(1)      37(1)       2(1)      25(1)       0(1)  
    C(5)     32(1)      20(1)      30(1)      -2(1)      17(1)       3(1)  
    C(6)     52(1)      16(1)      58(1)      -2(1)      42(1)      -3(1)  
    C(7)     20(1)      15(1)      33(1)       2(1)       8(1)      -1(1)  
    C(8)     27(1)      17(1)      38(1)       1(1)       9(1)       0(1)  
    _________________________________________________________________ 
 
  
 
APPENDIX MM 
HYDROGEN COORDINATES (x 10
4
) AND ISOTROPIC DISPLACEMENT 
PARAMETERS (A^2 x 10^3) FOR VENKAT35 
________________________________________________________________  
                         x             y             z           U(eq)          
________________________________________________________________   
   
          H(2N)        6339(19)      2640(20)      5564(10)      25   
          H(3N)        5438(19)      5345(19)      6017(10)      24  
          H(4)         1668          1725          8088          38  
          H(5)         1538          3919          8079          33  
          H(6A)        4809           992          5737          62  
          H(6B)        4381           525          6503          62  
          H(6C)        5830           936          6386          62  
          H(7A)        6294          6763          5018          27  
          H(7B)        7302          6787          5678          27  
          H(8A)        4669          7479          5772          41  
          H(8B)        5839          8427          5783          41  
          H(8C)        5670          7495          6433          41  
         _____________________________________________________________ 
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